

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
24 January 2002 (24.01.2002)

PCT

(10) International Publication Number
WO 02/06278 A1

- (51) International Patent Classification⁷: C07D 413/14, 413/12, A61K 31/42
- (21) International Application Number: PCT/IB01/01262
- (22) International Filing Date: 16 July 2001 (16.07.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
654/DEL/2000 17 July 2000 (17.07.2000) IN
- (71) Applicant (for all designated States except US): RANBAXY LABORATORIES LIMITED [IN/IN]; 19 Nehru Place, New Delhi 110 019 (IN).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): MEHTA, Anita [IN/IN]; L-19/3, Phase II, DLF Qutab Enclave, Gurgaon 122001, Haryana (IN). ARORA, Sudershan, K. [US/IN]; B-5/5, Phase - I, DLF Qutab Enclave, Gurgaon 122002 (IN). DAS, Biswajit [IN/IN]; 448, Mandakini Enclave, Alaknanda, Kalkaji, New Delhi 110 019, Maharashtra (IN). RAY, Abhijit [IN/IN]; C-380, Sarita Vihar, New Delhi 110 044, Maharashtra (IN). RUDRA, Sonali [IN/IN]; M-7, Kalkaji, New Delhi 110 019, Maharashtra (IN). RATTAN, Ashok [IN/IN]; B-481, Sarita Vihar, New Delhi 110 044, Maharashtra (IN).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
- with international search report
 - before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS

(57) Abstract: The present invention relates to certain substituted phenyl oxazolidinones and to processes for the synthesis of the same. This invention also relates to pharmaceutical compositions containing the compounds of the present invention as anti-microbials. The compounds are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including gram-positive aerobic bacteria such as multiply-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms such as *Bacterioides* spp. and *Clostridia* spp. species, and acid fast organisms such as *Mycobacterium tuberculosis*, *Mycobacterium avium* and *Mycobacterium* spp.

WO 02/06278 A1

OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS

FIELD OF THE INVENTION

The present invention relates to certain substituted phenyl oxazolidinones and to processes for the synthesis of the same. This invention also relates to pharmaceutical compositions containing the compounds of the present invention as antimicrobials. The compounds are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including gram-positive aerobic bacteria such as multiply-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms such as *Bacterioides* spp. and *Clostridia* spp. species, and acid fast organisms such as *Mycobacterium tuberculosis*, *Mycobacterium avium* and *Mycobacterium* spp.

BACKGROUND OF THE INVENTION

Increasing antibacterial resistance in Gram positive bacteria has presented a formidable treatment problem. The enterococci, although traditionally non virulent pathogens, have been shown, when associated with Vancomycin resistance, to have an attributable mortality of approximately 40%. *Staphylococcus aureus*, the traditional pathogen of post operative wounds, has been resistant to Penicillin due to production of penicillinases. This resistance was overcome by the development of various penicillinase stable β lactams. But the pathogen responded by synthesizing a modified target penicillin binding protein- 2' leading to less affinity for β lactam antibiotics and a phenotype known as Methicillin Resistant *S. aureus* (MRSA). These strains, till recently were susceptible to Vancomycin, which inspite of its various drawbacks, has become the drug of choice for MRSA infections. *Streptococcus pneumoniae* is a major pathogen causing

pneumonia, sinusitis and meningitis. Until very recently it was highly susceptible to penicillin. Recently though, different PBP 2' strains with different susceptibility to penicillin have been reported from across the globe.

Oxazolidinones are a new class of synthetic antimicrobial agents which kill gram positive pathogens by inhibiting a very early stage of protein synthesis. Oxazolidinones inhibit the formation of ribosomal initiation complex involving 30S and 50S ribosomes leading to prevention of initiation complex formation. Due to their novel mechanism of action, these compounds are active against pathogens resistant to other clinically useful antibiotics.

WO93/23384 application discloses phenyloxazolidinones containing a substituted diazine moiety and their uses as antimicrobials.

WO93/09103 application discloses substituted aryl and heteroaryl- phenyl-oxazolidinones useful as antibacterial agents

WO90/02744 application discloses 5-indolinyl-5 β -amidomethyloxazolidinones, 3-(fused ring substituted) phenyl-5 β -amidomethyloxazolidinones which are useful as antibacterial agents.

European Patent Publication 352,781 discloses phenyl and pyridyl substituted phenyl oxazolidinones.

European Patent Application 312,000 discloses phenylmethyl and pyridinylmethyl substituted phenyl oxazolidinones.

U.S. Patent No. 5,254,577 discloses nitrogen heteroaromatic rings attached to phenyloxazolidinone.

U.S. Patents No. 5,547,950 and 5,700,799 also disclose the phenyl piperazinyl oxazolidinones.

5 Other references disclosing various phenyloxazolidinones include U.S. Patents No. 4,801,600 and 4,921,869; Gregory W.A., *et al.*, *J.Med.Chem.*, 32, 1673-81 (1989); Gregory W.A., *et al.*, *J.Med.Chem.*, 33, 2569-78 (1990); Wang C., *et al.*, *Tetrahedron*, 45, 1323-26 (1989); Brittelli, *et al.*, *J.Med. Chem.*, 35, 1156 (1992); and *Bio-organic and Medicinal Chemistry Letters*, 9, pp. 2679-2684, 1999.


10 SUMMARY OF THE INVENTION

The objective of this invention is to synthesize, identify and profile oxazolidinone molecules which have good activity against multiply resistant gram positive pathogens like MRSA, VRE and PRSP. Some of these molecules have activity against MDR-TB and MAI strains, while others have significant activity against important anaerobic
15 bacteria.

The compounds of the present invention are related by their substituted phenyloxazolidinone ring structure in the compounds disclosed to the publications described above except that the subject compounds have a diazine moiety attached to the phenyloxazolidinone which is further substituted by heterocyclic, aryl, substituted aryl,
20 heteroaromatic ring therefore the compounds are unique and have superior antibacterial activity.

Another object of the present invention is to provide processes for the novel phenyloxazolidinones derivatives that exhibit significantly greater antibacterial activity, than available with the present compounds against multiply resistant gram positive pathogens like MRSA, VRE and PRSP against MDR-TB and MAI strains, in order to provide safe and effective treatment of bacterial infections.

In order to achieve the above-mentioned objectives and in accordance with the purpose of the invention as embodied and broadly described herein, there is provided a process for the synthesis of novel phenyloxazolidinone derivatives represented by Formula I



FORMULA I

wherein

T is five to seven membered heterocyclic ring, aryl, substituted aryl, bound to the ring C with a linker w, preferred forms of T are selected from aryl and five membered heteroaryl which are further substituted by a group represented by R, wherein R is selected from the group consisting of -CN, COR₅, COOR₅, N(R₆, R₇), CON(R₆, R₇), CH₂NO₂, NO₂, CH₂R₈, CHR₉, -CH=N-OR₁₀, -C=CH-R₅, wherein R₅ is selected from H, optionally substituted C₁-C₁₂, alkyl, C₃₋₁₂, cycloalkyl, aryl,

heteroaryl, R_6 and R_7 , are independently selected from H, optionally substituted C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy; R_8 and R_9 are independently selected from H, C_{5-6} alkyl, F, Cl, Br, C_{1-12} alkyl substituted with one or more of F, Cl, Br, I, OR_5 , SR_4 , $N(R_6, R_7)$ wherein R_5 is selected from H, C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkyl substituted with one or more F, Cl, Br, I or OH and R_6 and R_7 are the same as defined earlier, R_5 is selected from H, optionally substituted C_{5-12} alkyl, C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkyl, aryl, heteroaryl, n is an integer in the range from 0 to 3;

X is CH, CH-S, CH-O and N;

Y and Z are independently selected from hydrogen, C_{1-6} alkyl, C_{3-12} and cycloalkyl C_{0-3} bridging groups;

U and V are independently selected from optionally substituted C_{1-6} alkyl, F, Cl, Br, C_{1-12} alkyl substituted with one or more of F, Cl, Br, I, preferably U and V are hydrogen or fluoro;


W is selected from the group CH_2 , CO, CH_2NH , $-NHCH_2$, $-CH_2NHCH_2$, $-CH_2-N(R_{11})CH_2-$, $CH_2(R_{11})N-$, $CH(R_{11})$, S, $CH_2(CO)$, NH wherein R_{11} is optionally substituted C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkyl, aryl, heteroaryl; and,

R_1 is selected from the group consisting of $-NHC(=O)R_2$ wherein R_2 is hydrogen, C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkyl substituted with one or more of F, Cl, Br, I or OH, $N(R_3, R_4)$, $-NR_2C(=S)R_3$, $-NR_2C(=S)SR_3$ wherein R_2 is the

same as defined above, R_3, R_4 are independently selected from hydrogen, C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkyl substituted with one or more of F, Cl, Br, I or OH.

Preferred compounds of Formula I have R_1 as acetamide and the most preferred compounds in this series would be prepared as the optically pure enantiomers having the (S)-configuration according to the Cahn-Ingold-Prelog notation at C_5 of the oxazolidinone ring. The (S)-enantiomer of this series of compounds is preferred since it has two times more antibacterial activity than the corresponding racemic compound. The scope of the individual isomers and mixture of enantiomers of the structural Formula I are also covered in this invention.

Still more preferred compounds of the Formula I containing D ring as furanyl, thienyl and pyrrolyl ring systems and further substituted by substitutions Q and P is represented by Formula II



FORMULA II

wherein

U and V are independently selected from optionally substituted C_{1-6} alkyl, F, Cl, Br, C_{1-12} alkyl substituted with one or more of F, Cl, Br, I, preferably **U and V** are hydrogen or fluoro;


X is CH, CH-S, CH-O and N;

5 **Y and Z** are independently selected from hydrogen, C_{1-6} alkyl, C_{3-12} and cycloalkyl C_{0-3} bridging groups; and,


W is selected from the group CH_2 , CO, CH_2NH , $-NHCH_2$, $-CH_2NHCH_2$, $-CH_2-N(R_{11})CH_2-$, $CH_2(R_{11})N-$, $CH(R_{11})$, S, $CH_2(CO)$, NH wherein R_{11} is optionally substituted C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkyl, aryl, heteroaryl.

10 Preferred compounds of Formula II of this invention are those when **Q and P** are independently selected from the group consisting of -CN, COR_5 , $COOR_5$, N (R_6 , R_7), $CON(R_6, R_7)$, CH_2NO_2 , NO_2 , CH_2R_8 , CHR_9 , $-CH=N-OR_{10}$, $C=CH-R_5$, wherein R_5 is selected from the group consisting of H, optionally substituted C_{1-12} alkyl, C_{3-12} cycloalkyl, aryl, or heteroaryl; R_6 , R_7 are independently selected from H, optionally substituted C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, R_8 , R_9 and are independently selected
15 from the group consisting of H, C_{1-6} alkyl, F, Cl, Br, C_{1-12} alkyl substituted with one or more of F, Cl, Br, I, OR_4 , SR_4 , $N(R_6, R_7)$, $R_{10} = H$, optionally substituted C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkyl, aryl, heteroaryl except $W = (CO)$, **Q and P** = H.


In the more preferred compounds represented by Formula II ring C may be 6-8 membered in size and the larger rings may have either two or three carbons between each nitrogen atom, for example:




The ring C may be bridged to form a bicyclic system as shown below:




When ring C is optionally substituted at positions Y and Z with alkyl groups, cycloalkyl groups, fluoro group, carboxylic and corresponding esters, amides, substituted alkyls or bridging alkyl groups are as shown below:




When ring C is 6 membered in size and X is -CH-(NHR), the following rings are preferred ones wherein R₁₁ is the same as defined earlier.



In addition to the above, ring C also includes the following structures:



Still more preferred compounds of Formula II when M = Sulphur is represented by Formula III



FORMULA III

wherein

U and V are independently selected from optionally substituted C_{1-6} alkyl, F, Cl, Br, C_{1-12} alkyl substituted with one or more of F, Cl, Br, I, preferably U and V are hydrogen or fluoro;

5 X is CH, CH-S, CH-O and N;

Y and Z are independently selected from hydrogen, C_{1-6} alkyl, C_{3-12} and cycloalkyl C_{0-3} bridging groups;

10 W is selected from the group CH_2 , CO, CH_2NH , $-NHCH_2$, $-CH_2NHCH_2$, $-CH_2-N(R_{11})CH_2-$, $CH_2(R_{11})N-$, $CH(R_{11})$, S, $CH_2(CO)$, NH wherein R_{11} is optionally substituted C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkyl, aryl, heteroaryl; and,

15 Q and P are independently selected from the group consisting of $-CN$, COR_5 , $COOR_5$, $N(R_6, R_7)$, $CON(R_6, R_7)$, CH_2NO_2 , NO_2 , CH_2R_8 , CHR_9 , $-CH=N-OR_{10}$, $C=CH-R_5$, wherein R_5 is selected from the group consisting of H, optionally substituted C_{1-12} alkyl, C_{3-12} cycloalkyl, aryl, or heteroaryl; R_6 , R_7 are independently selected from H, optionally substituted C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, R_8 , R_9 and are independently selected from the group consisting of H, C_{1-6} alkyl, F, Cl, Br, C_{1-12} alkyl substituted with one or more of F, Cl, Br, I, OR_4 , SR_4 , $N(R_6, R_7)$, $R_{10} = H$, optionally substituted C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkyl, aryl, heteroaryl except $W = (CO)$, Q and P = H.

20

More preferred Q, P substitutions are nitro, aldehydes and halides.


Preferably W is selected from the groups consisting of CH_2 , C(=O) , C(=O)-C(=O) , CH_2NH , -NHCH_2 , $\text{-CH}_2\text{NHCH}_2$, $\text{-CH}_2\text{-N(CH}_3\text{)CH}_2\text{-}$, $\text{CH}_2\text{ (CH}_3\text{)N -}$, $\text{CH (CH}_3\text{)}$, S and $\text{CH}_2\text{(C=O)}$, -NH . The most preferred compounds of Formula III are as follows:

5 $\text{-(S)-N-}[[3\text{-}[4\text{-}[4\text{-(N-methyl-N-2-thienyl(5-nitro)methyl)aminopiperidine-1-yl]}\text{-3-fluorophenyl}]\text{-2-oxo-oxazolidin-5-yl}]\text{ methyl}]\text{acetamide}$

$\text{-(S)-N}[[3\text{-}[3\text{-Fluoro-4-[N-1[4-{2-(2-thienyl)dicarbonyl}]\text{piperazinyl}]\text{phenyl}]\text{2-oxo-5-oxazolidinyl}]\text{ methyl}]\text{acetamide}$

10 $\text{-(S)-N}[[3\text{-}[3\text{-Fluoro-4-[N-1[4-(5-nitro-2-thienoyl)]piperazinyl}]\text{phenyl}]\text{2-oxo-5-oxazolidinyl}]\text{methyl}]\text{ acetamide hydrochloride}$

Still more preferred compounds of Formula II is represented by Formula IV



15 **FORMULA IV**

containing oxygen atom in ring D of Formula II, wherein

U and V are independently selected from optionally substituted C₁₋₆ alkyl, F, Cl, Br, C₁₋₁₂ alkyl substituted with one or more of F, Cl, Br, I, preferably U and V are hydrogen or fluoro;

X is CH, CH-S, CH-O and N;

5 Y and Z are independently selected from hydrogen, C₁₋₆ alkyl, C₃₋₁₂ and cycloalkyl C₀₋₃ bridging groups;

W is selected from the group CH₂, CO, CH₂NH, -NHCH₂, -CH₂NHCH₂, -CH₂-N (R₁₁) CH₂-, CH₂ (R₁₁) N-, CH (R₁₁), S, CH₂(CO), NH wherein R₁₁ is optionally substituted C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkyl, aryl, heteroaryl; and,

10 Q and P are independently selected from the group consisting of -CN, COR₅, COOR₅, N (R₆, R₇), CON (R₆, R₇), CH₂NO₂, NO₂, CH₂R₈, CHR₉, -CH=N-OR₁₀, C=CH-R₅, wherein R₅ is selected from the group consisting of H, optionally substituted C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, aryl, or heteroaryl; R₆, R₇ are independently selected from H, optionally substituted C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, C₁₋₆ alkoxy, R₈, R₉ and are independently selected from the group consisting of H, C₁₋₆ alkyl, F, Cl, Br, C₁₋₁₂ alkyl substituted with one or more of F, Cl, Br, I, OR₄, SR₄, N(R₆, R₇), R₁₀ = H, optionally substituted C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkyl, aryl, heteroaryl except W= (CO), Q and P=H.

20 More preferred Q and P substitutions are nitro, aldehydes and halides.

Preferably W is selected from the groups consisting of CH_2 , C(=O) , C(=O)-C(=O) , CH_2NH , $-\text{NHCH}_2$, $-\text{CH}_2\text{NHCH}_2$, $-\text{CH}_2-\text{N}(\text{CH}_3)\text{CH}_2-$, $\text{CH}_2(\text{CH}_3)\text{N}-$, $\text{CH}(\text{CH}_3)$, S, $\text{CH}_2(\text{C=O})$, and $-\text{NH}$.

The most preferred compounds of Formula IV are as follows :

5 $-(S)-N-[[3-\text{Fluoro}-4-[N-1[4-(5\text{-nitro}-2\text{-furoyl})\text{piperazinyl}]\text{phenyl}]-2\text{-oxo}-5\text{-oxazolidinyl}]\text{methyl}]\text{acetamide}$.

$-(S)-N-[[3-[3\text{-fluoro}-4-[N-1-[4-\{2\text{-furyl}-(5\text{-nitro})\text{methyl}\}]\text{piperazinyl}]\text{phenyl}]-2\text{-oxo}-5\text{-oxazolidinyl}]\text{methyl}]\text{acetamide}$.

10 $-(S)-N-[[3-[4-[4-(N\text{-methyl}-N-(5\text{-nitro}-2\text{-furoyl})\text{aminopiperidine}-1\text{-yl}]-3\text{-fluorophenyl}]-2\text{-oxo}-\text{oxazolidin}-5\text{-yl}]\text{methyl}]\text{acetamide}$.

$-(S)-N-[[3-[4-[4-(N\text{-methyl}-N-2\text{-furyl}-(5\text{-nitro})\text{methyl})\text{aminopiperidine}-1\text{-yl}]-3\text{-fluorophenyl}]-2\text{-oxo}-\text{oxazolidin}-5\text{-yl}]\text{methyl}]\text{acetamide}$.

The compounds of the present invention are useful as antimicrobial agents, effective against a number of human and veterinary pathogens, particularly aerobic
15 Gram-positive bacteria, including multiply-antibiotic resistant staphylococci and streptococci, as well as anaerobic organisms such as *Mycobacterium tuberculosis* and other mycobacterium species.

For preparing pharmaceutical compositions from the compounds described by this invention, inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid
20 form preparations include powders, tablets, dispersible granules, capsules, cachets,

suppositories, and ointments. A solid carrier can be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, or tablets disintegrating agents; it can also be as finely divided solid which is in admixture with the finely divided active compound. For the preparation of tablets, the active compound is mixed with carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain from about 5 to about 70 percent of the active ingredient. Suitable solid carriers are lactose, pectin, dextrin, starch, gelatin, tragacanth, low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component (with or without other carriers) is surrounded by carrier, which is thus in association with it. Similarly, capsules can be used as solid dosage forms suitable for oral administration.

Liquid form preparations include solutions, suspensions, and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection. Such solutions are prepared so as to be acceptable to biological systems (isotonicity, pH, etc.). Liquid preparations can also be formulated in solution in aqueous polyethylene glycol solution. Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavours, stabilizing, and thickening agents as desired. Aqueous suspension suitable for oral use can be made by dispersing the finely divided active component in water with viscous

material, i.e., natural or synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other well-known suspending agents.

Ointment preparations contain heavy metal salts of a compound of Formula I with a physiologically acceptable carrier. The carrier is desirably a conventional water-dispersible hydrophilic or oil-in-water carrier, particularly a conventional semi-soft or cream-like water-dispersible or water soluble, oil-in-water emulsion infected surface with a minimum of discomfort. Suitable compositions may be prepared by merely incorporating or homogeneously admixing finely divided compounds with the hydrophilic carrier or base or ointment.

Preferably, the pharmaceutical preparation is in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete capsules, powders in vials or ampoules, and ointments capsule, cachet, tablet, gel, or cream itself or it can be the appropriate number of any of these packaged forms.

The quantity of active compound in a unit dose of preparation may be varied or adjusted from less than 1 mg to 100 mg according to the particular application and the potency of the active ingredient.

In therapeutic use as agents for treating bacterial infections the compounds utilized in the pharmaceutical method of this invention are administered at the initial dosage of about 3 mg to about 40 mg per kilogram daily. The dosages, however, may be

varied depending upon the requirements of the patient and the compound being employed. Determination of the proper dosage for a particular situation is within the smaller dosages which are less than the optimum dose. Small increments until the optimum effect under the daily dosage may be divided and administered in portions during the day if desired.

In order to achieve the above mentioned objects in accordance with the purpose of the invention as embodied and broadly described herein, there are provided process for the synthesis of compounds of Formulae I, II, III and IV. Pharmaceutically acceptable non-toxic acid addition salts of the compounds of the present invention of Formulae I, II, III and IV may be formed with inorganic or organic acids, by methods well known in the art.

The present invention also includes within its scope prodrugs of the compounds of Formulae I, II, III and IV. In general, such prodrugs will be functional derivatives of these compounds which readily get converted in vivo into defined compounds. Conventional procedures for the selection and preparation of suitable prodrugs are known.

The invention also includes pharmaceutically acceptable salts, the enantiomers, diastereomers, N-oxides, prodrugs, metabolites in combination with pharmaceutically acceptable carrier and optionally included excipient.


Other objects and advantages of the invention will be set forth in the description which follows, and in part will be apparent from the description, or may be learned by the

practice of the invention. The objects and the advantages of the invention may be released and obtained by means of the mechanism and combination pointed out in the appended claims.

DETAILED DESCRIPTION OF THE INVENTION

The compounds of the present invention may be prepared by following the reaction sequences as depicted in the schemes defined below.

Mainly five different amines of Formula V



FORMULA V

identified as five different cores, namely

-(S)-N-[[3-[3-Fluoro-4-(N-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide (core I);

-(S)-N-[[3-[3-Fluoro[4-[3-(1 α ,5 α ,6 α)-6-[N-methyl]amino]-3-azabicyclo-[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide (core II);

-(S)-N-[[3-[3-Fluoro[4-[3-(1 α ,5 α ,6 α)-6-[N-methyl] amino methyl]-3-azabi-cyclo-[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl] methyl]acetamide (core III);

-(S)-N-[[3-[4-[4-N-methylamino piperidin-1-yl]-3-fluorophenyl]-2-oxo-oxazolidin-5-yl]methyl acetamide (core IV); and,

5 -(S)-N-[[3-[3[Fluoro-4-(N-1-homopiperaziny)]phenyl]-2-oxo-5-oxazolidinyl]-methyl] acetamide (core V),


were used for analoguing purposes.

Key intermediate amines of Formula V for the analogue preparation were prepared from commercially available reagents wherein G in amines of Formula V is defined as NH, CH(NHR), -CH-CH₂NHR wherein R is H, ethyl, methyl, isopropyl, acetyl, cyclopropyl, alkoxy, or acetyl and U, V, Y and Z are as defined for Formula II. Some amines of Formula V are already known in the literature and are given by reference and if they have been made for the first time or by a different procedures or variation of known procedure they are described in detail in the experimental section.


15 Optically pure amines of Formula V could be obtained either by one of a number of asymmetric syntheses or alternatively by resolution from a racemic mixture by selective crystallization of a salt prepared, with an appropriate optically active acid such as dibenzoyl tartrate or 10-camphorsulfonic acid, followed by treatment with base to afford the optically pure amine.

20 The compounds of the present invention represented by general Formula I may be prepared by the method of reaction in Scheme I:

SCHEME-I



FORMULA V



FORMULA I


15 In Scheme I, the heteroaromatic group with the corresponding appendage can be introduced on the nitrogen atom of ring C of compounds of Formula V by one of the

methods described below to given Formula I, wherein R_{12} is a suitable leaving group well known to one of ordinary skill in the art such as fluoro, chloro, bromo, SCH_3 , $-SO_2CH_3$, $-SO_2CF_3$ or OC_6H_5 etc. and G in amines of Formula V is defined as NH , $CH(NHR_{13})$, $-CH-CH_2NHR_{13}$ wherein R_{13} is H, ethyl, methyl, isopropyl, acetyl, cyclopropyl, alkoxy or acetyl U, V, Y and Z are as defined for Formula I earlier.

Amine of structure of Formula V is reacted with a heteroaromatic compound of Formula R-T-W- R_{12} wherein R, T, W are the same as defined for Formula I earlier. For the preparation of compounds of Formula I when W is equal to CH_2 corresponding aldehyde can be used through a process of reductive amination and is attached to amine of Formula V.

Similarly, for the preparation of compound of Formula I wherein W is equal to $C=O$ corresponding acid can be used and the amino of Formula V can be acylated through activated esters in the presence of condensing agents such as 1,3-dicyclohexylcarbodiimide (DCC) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC). Other methods of acylation can also be employed.

Alternatively, the compounds having carbonyl link can also be made by reacting heteroaromatic compound of the Formula VI




FORMULA VI

such as N- methyl pyrrole with the intermediate amine of Formula V in the presence of triphosgene or phosgene. Carbonyl linkers may also be introduced between hetero-aromatic compound such as 3- bromothiophene and amine of Formula V with carbon monoxide and the catalyst such as Pd (PPh₃)₂Cl₂. Extended chain pyrroles having
5 dicarbonyl linkers can also be obtained from treatment with oxalyl chloride and amine of the Formula V.


The reduction of the carbonyl linkers using the standard reducing agents results in the formation of methylene linkers.

Preparation of the compound of Formula I as represented by Formula II (where
10 heterocycle is 5 membered ring) is accomplished as exemplified below by three methods A, B and C as shown in Scheme II:


SCHEME- II



FORMULA V



FORMULA VI



FORMULA II

Method A:

Amine of structure V is reacted with a heteroaromatic compound of Formula VI having R_{12} as a suitable leaving group defined earlier for Scheme I. Q, P and M are as defined for Formula II.

5 The reaction is done in a suitable solvent such as dimethylformamide, dimethylacetamide, ethanol or ethylene glycol at a suitable temperature in the range of -70°C to 180°C to afford compounds of Formula I. The presence of a suitable base such as triethylamine, diisopropyl amine, potassium carbonate, sodium bicarbonate is useful in some cases to improve the yield of the reaction.

10 **Method B:**

Reductive alkylation of the amine intermediate of Formula V, with the corresponding heterocyclic aldehydes of the Formula VI, such as furaldehyde (Q, P = H, M=O; R_{12} is CHO) using known reducing agents well known to one of ordinary skill in the art such as sodium triacetoxyborohydride or sodium cyanoborohydride gave the
15 products of Formula II wherein $W=CH_2$ as shown in the Scheme II.

Method C :


Acylation of intermediate amines of Formula V with heterocyclic acid of Formula VI, such as 2- furoic acid (Q,P = H; M=O, $R_{12} =COOH$) gave products of Formula II, wherein $W=CO$, as shown in the Scheme II wherein U, V, Y, Z, X, W, M, P, Q and R_{12}
20 are the same.

-(S)-N[[3-[3-Fluoro-4-[N-1[4-(5-nitro-2-thienoyl)]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl] acetamide hydrochloride was prepared using this method.

Alternatively, the compounds having carbonyl link can also be made by reacting heteroaromatic compound of the Formula VI such as N- methyl pyrrole with the intermediate amine of Formula V in the presence of triphosgene or phosgene. Carbonyl linkers may also be introduced between heteroaromatic compound such as 3-bromothiophene and amine of Formula V with carbon monoxide and the catalyst such as Pd (PPh ₃)₂Cl₂. Extended chain pyrroles having dicarbonyl linkers can also be obtained from treatment with oxalyl chloride and amine of the Formula V.


The reduction of the carbonyl linkers using the standard reducing agents results in the formation of methylene linkers.

SCHEME- III




FORMULA VII

1- 5 STEPS




FORMULA VIII

The compounds prepared by Scheme I represented by Formula VII



FORMULA VII

were further used as starting compounds for further derivatisation as represented by Scheme III wherein U,V,Y,Z,X,W,P,Q, n and M are the same as defined earlier. The group R₁₄ was transformed in one to five steps into final compounds of Formula VIII




FORMULA VIII

wherein U,V,Y,Z, n, X,W,P and M are the same as defined earlier containing transformed group R₁₅. In most cases the R₁₄ group in starting compounds were compounds containing R₁₄ as aldehyde and ketones.

The following compounds are exemplified in Scheme- IIIA, IIIB and IIIC.

SCHEME- III A




(S)-N-[[3-[3-Fluoro-4-[N-1 {2-furyl-[4-(5-hydroxymethyl)methyl}}] piperazinyl]-2-oxo-5-oxazolidinyl]methyl] acetamide represented by Formula X was prepared by reducing aldehyde of Formula IX with sodium borohydride.


5 (S)-N-[[3-[3-fluoro-4-[N-1 {2-furyl-[4-(5-fluoromethyl) methyl}}]piperazinyl]-2-oxo-5-oxazolidinyl]-methyl] acetamide of Formula XI ($R_{16} = CH_2F$) was prepared by reacting (S)-N-[[3-[3-Fluoro-4-[N-1 {2-furyl-[4-(5-hydroxymethyl)methyl}}] piperazinyl]-2-oxo-5-oxazolidinyl] methyl] acetamide by reacting Formula X with diethylamino sulfurtrifluoride.

10 (S)-N-[[3-[3-fluoro-4-[N-1 {2-furyl-[4-(5-difluoromethyl) methyl}}]piperazinyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide of Formula XI ($R_{16} = CH_2F_2$) was prepared by reacting (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-formyl)methyl}}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide of Formula IX with diethylamino sulfurtrifluoride as shown in Scheme IIIA.

SCHEME-III B



FORMULA IX



FORMULA XII

(S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-formyl)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide of Formula IX was reacted with *hydroxylamine and hydrazine hydrate* to give (S)-N-[[3-[3-Fluoro-4-[N-1-[4-(2-furyl-(5-aldoxime)methyl]]]piperazinyl] phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide of Formula XII

($R_{17} = \text{---}=\text{N-OH}$) and (S)-N-[[3-[3-Fluoro-4[N-1-[4-{2-furyl-(5-hydrazone)-methyl}]]-piperazinyl]-phenyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide of Formula XII


($R_{17} = \text{---}=\text{N-NH}_2$) (S)-N-[[3-[3-Fluoro-4-[N-1[4-{2-furyl(5-aldoxime(methyl-4-(N-carboxyamino)phenyl acetate)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-acetamide of Formula XII ($R_{17} = \text{---}=\text{N-O-C(=O)-NH-C}_6\text{H}_4\text{-CH}_2\text{COOCH}_3$) was made starting from (S)-N-[[3-[3-Fluoro-4-[N-1-[4-(2-furyl-(5-aldoxime)methyl]]] piperazinyl] phenyl]-

2-oxo-5-oxazolidinyl)methyl]acetamide of Formula XII ($R_{17} = \text{---}=\text{N-OH}$) and reacting with isocyanate.


(S)-N-[[3-[3-Fluoro-4-[N-1[4-{2-furyl(5-cyano)methyl}] piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide of Formula XII ($R_{17} = \text{CN}$) was prepared from (S)-N-[[3-[3-Fluoro-4-[N-1[4-{2-furyl(5-aldoxime)methyl}]piperazinyl] phenyl]-2-oxo-5-oxazolidinyl] methyl] acetamide of Formula XII ($R_{17} = \text{---}=\text{N-OH}$) by the use of triflic anhydride and triethylamine.

(S)-N-[[3-Fluoro-4-[N-1[5-(1,3-dioxane)-2-furylmethyl]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl] acetamide of Formula XII ($R_{17} = \text{---}\text{CH}(\text{O})\text{---}$) was made using (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-formyl)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl] acetamide of Formula IX with 1,3-propane diol and BF_3 etherate.


SCHEME - III C





FORMULA IX



FORMULA XIII



FORMULA XIV



(S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-carboxy)methyl}]piperaziny]phenyl]-2-oxo-5-oxazolidinyl)methyl] acetamide of Formula XIII was made using (S)-N-[[3-

Fluoro-4-[N-1[4-{2-furyl(5-formyl)methyl}] piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]-methyl] acetamide of Formula IX by oxidation with Ag₂O.

[[3-Fluoro-4-[N-1[5-(formamido)-2-furylmethyl]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide of Formula XIV $R_{10} = \text{---}\overset{\text{O}}{\underset{\text{NH}_2}{\text{C}}}\text{---}$ was made by reacting
 5 (S)-N-[[3-Fluoro-4-[N-1[4-(2-furyl- (5-carboxyethyl)methyl)piperazinyl] phenyl]- 2-oxo-5-oxazolidinyl]methyl] acetamide with aqueous ammonia.

(S)-N-[[3-Fluoro-4-[N-1[5-(4-(tert butoxy carbonyl)amino piperidine)-2-furylmethyl]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide of Formula XIV $R_{10} = \text{---}\overset{\text{O}}{\underset{\text{N}}{\text{C}}}\text{---}$ was made by reacting (S)-N-[[3-Fluoro-4-[N-1[4-(2-furyl-(5-carboxy)methyl)piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide of Formula
 10 XIII with thionyl chloride and 4-(tert butoxy carbonyl)amino piperidine.

(S)-N -[[3-Fluoro-4-[N-1[5-(morpholine-1-carbonyl)-2-furylmethyl]piperazinyl]-phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide of Formula XIV $R_{10} = \text{---}\overset{\text{O}}{\underset{\text{N}}{\text{C}}}\text{---}$ was made by reacting (S)-N-[[3-Fluoro-4-[N-1[4-(2-furyl-(5-carboxy)methyl)-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide of Formula XIII with
 15 morpholine in the presence of oxalyl chloride.

The transformations effected are described in the experimental section. In the above synthetic methods where specific acids, bases, solvents, catalysts, oxidising agents, reducing agents etc. are mentioned, it is to be understood that the other acids, bases,
 20 solvents, catalysts, oxidising agents, reducing agents etc. may be used. Similarly, the reduction temperature and duration of the reaction may be adjusted according to the need.

An illustrative list of particular compounds according to the invention and capable of being produced by the above mentioned schemes include:

Compound No.	Chemical Name
--------------	---------------

- | | |
|----|-----------------------------------------------------------------------------------------------------------------------|
| 5 | 1. (S)-N-[[3-[3-Fluoro-4-[N-1-[4-(2-furoyl) piperazinyl]]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide |
| | 2. (S)-N-[[3-[3-Fluoro-4-[N-1[4-{2-furyl(5-formyl)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide |
| 10 | 3. (S)-N-[[3-Fluoro-4-[N-1[4-(2-furyl(5-carboxyethyl)methyl)piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide |
| | 4. (S)-N-[[3-Fluoro-4-[N-1[4-(5-bromo-2-furoyl)]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide |
| | 5. (S)-N-[[3-Fluoro-4-[N-1[4-(5-chloromethyl-2-furoyl)piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide |
| 15 | 6. (S)-N-[[3-Fluoro-4-[N-1[4-(5-nitro-2-furoyl)piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide |
| | 7. (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-(2-thienyl)dicarbonyl}]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide |
| 20 | 8. (S)-N[[3-[3-Fluoro-4-[N-1[4-(3-furoyl)]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]-methyl] acetamide |
| | 9. (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-furyl(5-bromo)methyl}]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide |
| | 10. (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-thienyl(5-chloro)methyl}]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide |
| 25 | 11. (S)-N[[3-[3-Fluoro-4-[N-1[4-(2-furylmethyl)]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide |
| | 12. (S)-N-[[3-[3-Fluoro-4-[N-1[4-(2-thienylmethyl)]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide |
| 30 | 13. (S)-N[[3-[3-Fluoro-4-[N-1[4-(2-thienylacetyl)]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide |

14. (S)-N-[[3-[3-Fluoro-4-[N-1[4-{2-thienyl(4-bromo)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
15. (S)-N-[[3-[3-fluoro-4-[N-1[4-{2-furyl(5-nitro)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
- 5 16. Hydrochloric salt of (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-nitro)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
17. Citrate salt of (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-nitro)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
18. (S)-N[[3-[3-Fluoro-4-[N-1[4-(2-pyrrolylmethyl)]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide
- 10 19. (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-thienyl(3-methyl)methyl}]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide
20. (S)-N[[3-[3-Fluoro-4-[N-1[4-(3-furylmethyl)]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide
- 15 21. (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-thienyl(5-methyl)methyl}]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide
22. (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-pyrrole(1-methyl)methyl}]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide
23. (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-thienyl(5-nitro)methyl}]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide
- 20 24. (S)-N[[3-[3-Fluoro-4-[N-1[4-[2-furyl{5-(N-thiomorpholinyl)methyl}methyl]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide
25. (S)-N[[3-[3-Fluoro-4-[N-1[4-[2-furyl{5-(N-morpholinyl)methyl}methyl]]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide
- 25 26. (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-acetoxymethyl)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
27. (S)-N-[[3-Fluoro-4-[N-1[4-{2-thienyl(5-bromo)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
28. (S)-N-[[3-Fluoro-4-[N-1[4-(5-nitro-2-furylmethyl)piperazinyl]phenyl]-2-oxo-oxazolidinyl]methyl]dichloroacetamide
- 30

29. (S)-N-[[3-[3-Fluoro-4-[N-1[4-(5-nitro-2-thienoyl)]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide hydrochloride
30. (S)-N-[[3-[3-Fluoro-4-[N-1[4-(2',2'-diphenyl-2'-hydroxyacetyl)]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide
- 5 31. (S)-N-[[3-[3-Fluoro[4-[3-(1 α ,5 α ,6 α)-6-[N-(5-nitro-2-furoyl)-N-methyl]amino]-3-azabicyclo-[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
32. (S)-N-[[3-[3-Fluoro[4-[3-(1 α ,5 α ,6 α)-6-[N-(3-furoyl)-N-methyl]amino]-3-azabicyclo-[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
33. (S)-N-[[3-[3-Fluoro[4-[3-(1 α ,5 α ,6 α)-6-[N-(5-bromo-2-furoyl)-N-methyl]amino]-3-azabicyclo-[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
- 10 34. (S)-N-[[3-[3-Fluoro[4-[3-(1 α ,5 α ,6 α)-6-[N-(5-nitro-2-thienylmethyl)-N-methyl]amino]-3-azabicyclo-[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
35. (S)-N-[[3-[3-Fluoro[4-[3-(1 α ,5 α ,6 α)-6-[N-(5-nitro-2-furylmethyl)-N-methyl]amino]-3-azabicyclo-[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
- 15 36. (S)-N-[[3-[3-Fluoro[4-[3-(1 α ,5 α ,6 α)-6-[N-(5-formyl-2-furylmethyl)-N-methyl]amino-methyl]-3-azabicyclo-[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
37. (S)-N-[[3-[3-Fluoro[4-[3-(1 α ,5 α ,6 α)-6-[N-(5-carboxyethyl-2-furylmethyl)-N-methyl]aminomethyl]-3-azabicyclo-[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
- 20 38. (S)-N-[[3-[3-Fluoro[4-[3-(1 α ,5 α ,6 α)-6-[N-(2-thiopheneacetyl)-N-methyl]amino-methyl]-3-azabicyclo-[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
39. (S)-N-[[3-[3-Fluoro[4-[3-(1 α ,5 α ,6 α)-6-[N-(5-nitro-2-thienylmethyl)-N-methyl]amino-methyl]-3-azabicyclo-[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
- 25 40. (S)-N-[[3-[3-Fluoro[4-[3-(1 α ,5 α ,6 α)-6-[N-(5-nitro-2-furylmethyl)-N-methyl]amino-methyl]-3-azabicyclo-[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
41. (S)-N-[[3-[4-[4-(N-methyl-N-2-furyl(5-formyl)methylaminopiperidine-1-yl]-3-fluorophenyl]-2-oxo-oxazolidin-5-yl]methyl]acetamide

42. (S)-N-[[3-[4-[4-(N-methyl-N-(3,5-difluorobenzoyl)aminopiperidine-1-yl]-3-fluorophenyl]-2-oxo-oxazolidin-5-yl] methyl]acetamide
43. (S)-N-[[3-[4-[4-(N-methyl-N-(5-bromo-2-furoyl)aminopiperidine-1-yl]-3-fluorophenyl]-2-oxo-oxazolidin-5-yl] methyl]acetamide
- 5 44. (S)-N-[[3-[4-[4-(N-methyl-N-(5-nitro-2-furoyl)aminopiperidine-1-yl]-3-fluorophenyl]-2-oxo-oxazolidin-5-yl] methyl]acetamide
45. (S)-N-[[3-[4-[4-(N-methyl-N-3-furoyl)aminopiperidine-1-yl]-3-fluorophenyl]-2-oxo-oxazolidin-5-yl] methyl]acetamide
46. (S)-N-{3-[4-[4-(N-methyl, N-2-furoyl)aminopiperidine-1-yl]-3-fluorophenyl]-2-oxo-oxazolidin-5-yl methyl]acetamide
- 10 47. (S)-N-{3-[4-[4-(N-methyl,2-thiopheneacetyl)aminopiperidine-1-yl]-3-fluorophenyl]-2-oxo oxazolidin-5-yl methyl]acetamide
48. (S)-N-[[3-[4-[4-(N-methyl-N-2furylmethyl) aminopiperidine-1-yl]-3-fluorophenyl]-2-oxo-oxazolidin-5-yl] methyl]acetamide
- 15 49. (S)-N-[[3-[4-[4-(N-methyl-N-3-furyl)aminopiperidine-1-yl]-3-fluorophenyl]-2-oxo-oxazolidin-5-yl] methyl]acetamide
50. (S)-N-[[3-[4-[4-(N-methyl-N-2-furyl(5-nitro)methyl)aminopiperidine-1-yl]-3-fluorophenyl]-2-oxo-oxazolidin-5-yl] methyl]acetamide
51. (S)-N-[[3-[4-[4-(N-methyl-N-2-thienyl(5-nitro)methyl)aminopiperidine-1-yl]-3-fluorophenyl]-2-oxo-oxazolidin-5-yl] methyl]acetamide
- 20 52. (S)-N-[[3-[4-[4-(N-methyl-N-2-thienylmethyl)aminopiperidine-1-yl]-3-fluorophenyl]-2-oxo-oxazolidin-5-yl] methyl]acetamide
53. (S)-N-[[3-[4-[4-(N-methyl-N-(5-methyl-2-thienylmethyl)aminopiperidine-1-yl]-3-fluorophenyl]-2-oxo-oxazolidin-5-yl] methyl]acetamide
- 25 54. (S)-N-{3-[4-[4-(N-methyl,2-(5-bromo)thienylmethyl)aminopiperidine-1-yl]-3-fluorophenyl]-2-oxo-oxazolidin-5-yl methyl]acetamide
55. (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-furyl(5-formyl)methyl}]homopiperaziny]]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide
- 30 56. (S)-N[[3-[3-Fluoro-4-[N-1[4-(2-thienylacetyl)]homopiperaziny]]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide

57. (S)-N-[[3-[3-Fluoro-4-[N-1[4-{2-thienyl(5-nitro)methyl}]homopiperazinyl]phenyl]2-oxo-5-oxazolidinyl)methyl]acetamide
58. (S)-N-[[3-[3-Fluoro-4-[N-1[4-(3-furylmethyl)]homopiperazinyl]phenyl]2-oxo-5-oxazolidinyl)methyl]acetamide
- 5 59. (S)-N-[[3-[3-fluoro-4-[N-1{2-furyl-[4-(5-difluoromethyl)methyl}]piperazinyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide
60. (S)-N-[[3-[3-Fluoro-4-[N-1-[4-(2-furyl-(5-aldoxime)methyl}] piperazinyl] phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide
61. (S)-N-[[3-[3-Fluoro-4-[N-1[4-{2-furyl(5-aldoxime(methyl-4-(N-carboxyaminophenyl acetate) methyl})piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide
- 10 62. (S)-N-[[3-[3-Fluoro-4[N-1-[4-{2-furyl-(5-hydrazone)-methyl}]piperazinyl]-phenyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide
63. (S)-N-[[3-[3-Fluoro-4-[N-1{2-furyl-[4-(5-hydroxymethyl)methyl}]piperazinyl]-2-oxo-5-oxazolidinyl)methyl]acetamide
- 15 64. (S)-N-[[3-[3-Fluoro-4-[N-1[4-{2-furyl(5-cyano)methyl}] piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide
65. (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-carboxy)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl] acetamide
66. (S)-N-[[3-Fluoro-4-[N-1[5-(1,3-dioxane)-2-furylmethyl]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl] acetamide
- 20 67. (S)-N-[[3-Fluoro-4-[N-1[5-(formamido)-2-furylmethyl]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl] acetamide
68. (S)-N-[[3-Fluoro-4-[N-1[5-(morpholine-1-carbonyl)-2-furylmethyl]piperazinyl]-phenyl]-2-oxo-5-oxazolidinyl)methyl] acetamide
- 25 69. (S)-N-[[3-Fluoro-4-[N-1[5-(4-(tert butoxy carbonyl)amino piperidine)-2-furylmethyl]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl] acetamide
70. (S)-N-[[3-Fluoro-4-[N-1[4-{(Z)-2-methoxyimino-2-(2-furyl)acetyl}]piperazinyl]-phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide
- 30 71. (S)-N-[[3-[3-Fluoro[4-[3-(1 α ,5 α ,6 α)-6-[N-(2-thiopheneacetyl)-N-methyl]amino]-3-azabicyclo-[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide

72. (S)-N-[[3-[3-Fluoro[4-[3-(1 α ,5 α ,6 α)-6-[N-(5-formyl-2-furylmethyl)-N-methyl]-amino]-3-azabicyclo-[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl] methyl]acetamide
73. (S)-N-[[3-[3-Fluoro[4-[3-(1 α ,5 α ,6 α)-6-[N-(3-thienoyl)-N-methyl]amino]-3-azabicyclo[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl] methyl]acetamide
- 5 74. (S)-N-[[3-[3-fluoro-4-[N-1 {2-furyl-[4-(5-fluoromethyl) methyl}]piperazinyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide

Pharmacological Testing

10 The compounds of the invention display antibacterial activity when tested by the agar incorporation method. The following minimum inhibitory concentrations (μ g/ml) were obtained for representative compounds of the invention which are given below in the following tables.

GUIDE TO TABLE ABBREVIATIONS:

- 15
- 1) *S.aureus* ATCC 25923 --*Staphylococcus aureus* ATCC 25923
 - 2) MRSA 15187 --Methicillin Resistant *Staphylococcus aureus*
 - 3) *Ent. faecalis* ATCC 29212 --*Enterococcus faecalis* ATCC 29212
 - 4) *Ent. faecium* 6A -- *Enterococcus faecium* 6A Van[®], Cipro[®]
 - 20 5) *Strep. pne.* ATCC 6303 --*Streptococcus pneumoniae* ATCC 6303
 - 6) *Strep.pyog.* ATCC 19615 --*Streptococcus pyogenes*
 - 7) *S. epidermidis* - *Staphylococcus epidermidis* ATCC 12228

TABLE 1: MIC of compounds and standard antibiotics against important pathogens

Compound No.	<i>S. aureus</i> 25923	MRSA 15187	MRSA 562	MRSA 33	<i>E. faecalis</i> 29212	VRE 6A	<i>S. pyogenes</i> 19615	<i>S. pneum</i> 6303	<i>S. pneum</i> AB 34
02	1	2	1	2	8	8	8	4	8
14	4	2	2	2	2	2	2	4	4
60	2	2		2	8	16	4	8	8
66	2	2	2	2	16	16	8	8	8
12	8	8	8	8	8	8	4	8	8
62	2	2	1	2	8	8	8	8	8
61	8	8		8	8	8	8	8	8
15	2	2	2	2	2	1	1	1	2
01	2	2		4	2	2	1	2	1
27	2	2	2	2	2	4	1	2	0.5
16	2	4		4	2	4	0.5	1	1
17	2	2		2	2	4	1	2	1
71	8	8		8	8	8	4	4	2
04	2	2		2	2	1	2	1	1
05	16	4		4	8	8	4	4	4
06	1	0.5		0.5	1	1	2	2	2
10	8	4		4	8	4	1	4	8
23	8	8		8	8	8	1	8	8
33	4	4		4	4	4	0.5	8	4
73	8	8		8	8	8	1	4	8
72	8	4		4	8	8	0.25	4	4
32	8	8		8	8	8	1	4	4
08	2	1	1	1	1	1	1	2	4
07	2	2	2	2	2	2	0.5	2	2
34	1	1	1	1	1	1	2	4	4
71	4	4		4	4	4	2	4	4
29	0.25	<0.1	<0.1	<0.1	1	0.5	1	1	1
44	0.25	<0.1	<0.1	<0.1	0.25	<0.1	0.5	2	2
50	1	1	0.5	1	0.5	0.25	0.125	0.5	2
40	2	2	1	2	2	4	0.125	NG	2
51	2	1	1	1	4	4	0.5	NG	2
22	2	8	4	8	8	8	1	1	1
38	4	4	4	4	4	4	1	1	1
39	8	8	8	4	2	8	0.5	0.5	0.5
Linezolid	2	1	2	2	2	2	2	2	4
Vancomycin	1	0.5	0.5	0.5	4	>16	0.5	0.5	0.25
Linezolid	2	1	2	2	2	2	2	2	4
Vancomycin	1	0.5	0.5	0.5	4	>16	0.5	0.5	0.25

TABLE 2
Summary of *in vitro* Activity (MIC):

Bacteria	Number	Vancomycin		Linezolid		Penicillin G		Compound No. 29		Compound No. 44	
		MIC50	MIC90	MIC50	MIC90	MIC50	MIC90	MIC50	MIC90	MIC50	MIC90
G+ve	49	0.5	16	2	4	4	32	1	1	0.5	2
S.aureus	8	1	1	2	4	-	-	0.064	0.25	0.064	0.25
E.faecalis	7	16	16	4	16	-	-	1	1	0.064	0.25
S.pneumoniae	19	0.5	0.5	0.5	2	4	32	1	1	1	2

Bacteria	Compound no. 15		Compound No. 06		Compound No. 50		Compound No. 40	
	MIC50	MIC90	MIC50	MIC90	MIC50	MIC90	MIC50	MIC90
G+ve	1	2	1	2	1	2	1	2
S.aureus	2	2	1	1	1	2	2	4
E.faecalis	2	2	1	1	0.5	1	2	4
S.pneumoniae	2	4	2	2	1	2	1	1

TABLE 3
Geometric Mean of *in vitro* activity(MIC):

	Vancomycin	Linezolid	Penicillin G	Compound No. 44
Gram +ve	0.93	1.25	0.76	0.31
S.aureus	1	2.38	-	0.11
E.faecalis	9.75	4	-	0.11
S.pneumoniae	0.39	0.60	2.16	0.96

	Compound No. 15	Compound No. 06	Compound No. 50	Compound No. 40
Gram +ve	1.08	0.79	0.72	0.93
S.aureus	1.63	0.74	1	1.83
E.faecalis	1.6	0.92	0.42	2.38
S.pneumoniae	1.04	1.27	1.41	0.71

TABLE 4
Changes in MIC under different conditions

Compound No.	Agar MIC	Broth MIC	
		Normal MH broth	+ 50% Sheep serum
16	2	2	2
08	1	2	4
29	<0.1	0.25	0.5
44	<0.1	<0.1	0.25
Linezolid	2	1	2
Vancomycin	1	1	1

TABLE 5
Linezolid has 30% protein binding
In vitro and *in vivo* activity against MRSA 562

RBx	MIC ($\mu\text{g/ml}$)	ED50 (mg/kg body weight) PO
Vancomycin	0.5	8.84 (IV)
Linezolid	2	4.56
67	2	>25
15	2	4.33
04		>25
06	1	>25
08	1	25
71	4	>25
29	<0.1	>25
44	<0.1	>25
50	0.5	
07	2	>25

The in vitro antibacterial activity of the compounds were demonstrated by the agar incorporation method (NCCLS M 7 and M 100-S8 documents). Briefly, the compounds were dissolved in DMSO and doubling dilution of the compounds were incorporated into Mueller Hilton agar before solidification. Inoculum was prepared by suspending 4 to 5 colonies into 5 ml of normal saline solution and adjusting the turbidity to 0.5 Macfarland turbidity standard tables (1.5×10^8 CFU/ml), after appropriate dilutions, 10^4 CFU/spot was transferred into the surface of dried plate and incubated for 18 hours (24 hours for MRSN studies). The concentration showing no growth of the inoculated culture was recorded as the MIC. Appropriate ATCC standard strains were simultaneously tested and result recorded only when the MIC's against standard antibiotics were within the acceptable range.

The compounds of the present invention represented by general Formula I may be prepared by the method of reaction in Scheme I. Key intermediate amines of Formula V for the analogue preparation were prepared by the synthetic procedures described below from commercially available reagents. The compounds of Formula I were made by either Method A, B, or C.

Amines already known in the literature are given by reference and if they have been made by a different procedures they are described in detail.

Mainly five different amines of Formula V identified as five different cores namely

(S)-N-[[3-[3-Fluoro-4-(N-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl] methyl] acetamide (core I),

(S)-N-[[3-[3-Fluoro[4-[3-(1 α ,5 α ,6 α)-6-[N-methyl]amino]-3-azabicyclo-[3.1.0]hexane]benzyl]-2-oxo-5-oxazolidinyl]methyl] acetamide (core II),

(S)-N-[[3-[3-Fluoro[4-[3-(1 α ,5 α ,6 α)-6-[N-(5-nitro-2-furylmethyl)-N-methyl] amino]-3-azabicyclo-[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]methyl]-
5 acetamide (core III),

(S)-N-{3-[4-[4-N-methylaminopeperidin-1-yl]-3-fluorophenyl]-2-oxo-oxazol-
idin-5-yl]methyl acetamide (core IV), and

(S)-N-[[3-[3[Fluoro-4-(N-1-homopiperazinyl)phenyl]-2-oxo-5-oxazolidinyl]
methyl] acetamide (core V)

10 are shown in the examples given below.

Most of the compounds were characterized using NMR, IR and were purified by chromatography. Crude products were subjected to column chromatographic purification using silica gel (100-200 or 60-120 mesh) as stationery phase.

The examples mentioned below demonstrate the general synthetic procedure
15 as well as the specific preparation for the preparation for the preferred compound. The examples are given to illustrate the details of the invention and should not be constrained to limit the scope of the present invention.

EXAMPLE 1

Analogues of (S)-N-[[3-[3-Fluoro-4-(N-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide(core I)

20 The heteroaromatic group with the corresponding appendage can be introduced on the nitrogen atom of ring C of compounds of Formula I by one of the methods described below:

Method-A:

General procedure:

Amine of structure of Formula V is reacted with a heteroaromatic compounds of Formula VI having corresponding R₁₂ appendages such as -CH₂R₁₃, -COR₁₃ or -CH(CH₃)R₁₃ wherein R₁₃ is a suitable leaving group well known to one of ordinary skill in the art such as fluoro, chloro, bromo, SCH₃, -SO₂CH₃, -SO₂CF₃ or OC₆H₅ etc..

The reaction is done in a suitable solvent such as dimethylformamide, dimethylacetamide, ethanol or ethylene glycol at a suitable temperature in the range of -78°C to 180°C to afford compounds of Formula II. The presence of a suitable base such as triethylamine, diisopropyl amine, potassium carbonate, sodium bicarbonate is useful in some cases to improve the yield of the reaction.

The following compounds were made following this method:

Compound No. 01 (S)-N-[[3-[3-Fluoro-4-[N-1-[4-(2-furoyl) piperazinyl]]-phenyl]-2-oxo-5-oxazolidinyl] methyl]acetamide

(S)-N-[[3-[3-Fluoro-4-(N-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide prepared by the method given in U.S. Patent No. 5,700,799 (1.2g, 3.57 mmol) was dissolved in dry dimethyl formamide (35 ml). To this was added K₂CO₃ (2.47g; 17.87 mmol) and furoyl chloride (0.56 g, 10.68 mmol). The reaction mixture was stirred at 25°C for 5.0 hr. TLC of the reaction mixture was monitored. A faster moving spot was observed. Solvent was removed and the residue was dissolved in dichloromethane, washed with water, dried over sodium sulphate, and solvent was removed. The residue was digested with ether and filtered to yield 800 mg of white

crystalline solid 225.5.-226.5°C

δ ppm (CDCl₃) : 7.50-7.44 (m, 2H), 7.09-7.06 (m, 2H), 6.95-6.89 (m, 1H) 6.50 (bs, 1H) 4.76 (bs, 1H), 4.05-3.19 (m, 9H), 3.09 (bs, 4H), 2.02 (s, 3H).

Compound No. 02: (S)-N-[[3-[3-Fluoro-4-[N-1[4-(2-furyl(5-formyl)methyl]]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

The title compound was made with (S)-N-[[3-[3[Fluoro-4-(N-1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide and 5-chloromethyl 2-furfuraldehyde using Method A.

Compound No. 03: (S)-N-[[3-Fluoro-4-[N-1[4-(2-furyl(5-carboxyethyl)methyl)-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

The title compound was made with (S)-N-[[3-[3[Fluoro-4-(N-1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide ethyl-5-chloromethyl-2-furan-carboxylate using Method A.

Compound No. 04: (S)-N-[[3-Fluoro-4-[N-1[4-(5-bromo-2-furoyl)]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

The title compound was made with (S)-N-[[3-[3[Fluoro-4-(N-1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide and 5-bromo-2-furoyl chloride using Method A.

Compound No. 05: (S)-N-[[3-Fluoro-4-[N-1[4-(5-chloromethyl-2-furoyl)piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

The title compound was made with (S)-N-[[3-[3[Fluoro-4-(N-1-piperazinyl)-

phenyl]-2-oxo-5-oxazolidinyl)methyl acetamide and 5-chloromethyl-2-furoyl chloride using Method A.

Compound No. 06: (S)-N-[[3-Fluoro-4-[N-1[4-(5-nitro-2-furoyl)piperazinyl]phenyl]-2-oxo-5-oxazolidinyl] methyl]acetamide

5 The title compound was made with (S)-N-[[3-[3[Fluoro-4-(N-1-piperazinyl)-phenyl]-2-oxo-5-oxazolidinyl)methyl acetamide and 5-nitro -furoyl chloride using Method A.

Compound No. 07: (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-(2-thienyl)dicarbonyl}]-piperazinyl]phenyl]2-oxo-5-oxazolidinyl)methyl]acetamide

10 The title compound was made with (S)-N-[[3-[3[Fluoro-4-(N-1-piperazinyl)-phenyl]-2-oxo-5-oxazolidinyl)methyl acetamide and 2-thiophenglyoxylyl chloride using Method A.

δ ppm (CDCl₃): 7.84(m, 2H, Ar-H), 7.47(dd, 1H, Ar-H), 7.2(m, 1H, Ar-H),
7.07(d, 1H, Ar-H), 6.92(t, 1H, Ar-H), 5.98(t, 1H, NH), 4.76(m, 1H, CH), 4.0(t, 1H,
15 CH), 3.5-3.95 (m, 7H, CH₂), 3.15 (m, 2H, CH₂), 3.06 (m, 2H Cl₂), 2.02 (s, 3H, CH₃)

Compound No. 08: (S)-N[[3-[3-Fluoro-4-[N-1[4-(3-furoyl)]piperazinyl]phenyl]2-oxo-5-oxazolidinyl)methyl] cetamide

 The title compound was made with (S)-N-[[3-[3[Fluoro-4-(N-1-piperazinyl)-phenyl]-2-oxo-5-oxazolidinyl)methyl acetamide and 3-furoyl chloride using Method
20 A.

δ ppm (CDCl₃) : 8.06(s, 1H, Ar-H), 7.49(m, 2H, Ar-H), 7.09(d, 1H, Ar-H),

6.76(t, 1H, Ar-H), 6.57 (s, 1H, Ar-H), 6.03(br s, 1H, NH), 4.77 (m, 1H, CH), 4.2-3.5(m, 8H, CH₂), 3.06(m, 4H, CH₂), 2.02(s, 3H, CH₃)

Compound No. 09: (S)-N-[[3-[3-Fluoro-4-[N-1[4-{2-furyl(5-bromo)methyl}]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide

5 The title compound was made with (S)-N-[[3-[3[Fluoro-4-(N-1-piperazinyl)-phenyl]-2-oxo-5-oxazolidinyl]methyl acetamide and 5-bromo-2-chloromethylfuran using Method A.

10 δ ppm (CDCl₃): 7.47 (d, 1H, Ar-H), 7.06 (d, 1H, Ar-H), 6.91 (t, 1H, Ar-H), 6.47 (d, 1H, Ar-H), 6.32 (d, 1H, Ar-H), 5.98 (t, 1H, NH), 4.76 (m, 1H, CH), 4.02 (t, 1H, CH), 3.4-3.85 (m, 9H, CH₂), 3.07 (m, 4H, CH₂), 2.02 (s, 3H, CH₃).

Compound No. 10: (S)-N-[[3-[3-Fluoro-4-[N-1[4-{2-thienyl(5-chloro)methyl}]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide

15 The title compound was made with (S)-N-[[3-[3[Fluoro-4-(N-1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl acetamide and 5-chloro-2-chloromethylthiophene using Method A.

δ ppm (CDCl₃) :7.42 (dd, 1H, Ar-H), 7.05 (dd, 1H, Ar-H), 6.92 (t, 1H, Ar-H), 6.74 (d, 2H, Ar-H), 6.00 (m, 1H, CH), 4.74 (m, 1H, CH), 4.01 (t, 1H, CH), 3.3-3.8 (m, 5H, CH₂), 3.08 (m, 4H, CH₂), 2.66 (m 4H, CH₂) 2.01 (s, 3H, CH₃).

20 **Compound No. 11: (S)-N-[[3-[3-Fluoro-4-[N-1[4-(2-furylmethyl)]piperazinyl]phenyl]2-oxo-5-oxazolidinyl] methyl]acetamide**

The title compound was made with (S)-N-[[3-[3[Fluoro-4-(N-1-piperazinyl)-

phenyl]-2-oxo-5-oxazolidinyl)methyl acetamide and 2-chloromethylfuran using Method A.

δ ppm (CDCl₃): 7.49 (m, 2H, Ar-H), 7.07 (d, 1H, Ar-H), 6.91 (t, 1H, Ar-H), 6.51 (d, 1H, Ar-H), 6.4 (d, 1H, Ar-H), 6.1 (t, 1H, NH), 4.75 (m, 1H, CH), 4.1-3.25 (m, 10H, CH₂), 3.06 (m, 4H, CH₂), 2.03 (s, 3H, CH₃).

Compound No. 12: (S)-N-[[3-[3-Fluoro-4-[N-1[4-(2-thienylmethyl)]piperazinyl]-phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide

The title compound was made with (S)-N-[[3-[3-Fluoro-4-(N-1-piperazinyl)-phenyl]-2-oxo-5-oxazolidinyl)methyl acetamide and 2-chloromethylthiophen using Method A.

δ ppm (CDCl₃): 7.4 (m, 1H, Ar-H), 6.94 (m, 5H, Ar-H), 6.08 (t, 1H, NH), 4.71 (m, 1H, CH), 4.1-3.4 (m, 6H, CH₂), 3.08 (m, 4H, CH₂), 2.73 (m, 4H, CH₂), 1.98 (s, 3H, CH₃).

Compound No. 13: (S)-N[[3-[3-Fluoro-4-[N-1[4-(2-thienylacetyl)]piperazinyl]-phenyl]2-oxo-5-oxazolidinyl] methyl]acetamide

The title compound was made with (S)-N-[[3-[3-Fluoro-4-(N-1-piperazinyl)-phenyl]-2-oxo-5-oxazolidinyl)methyl acetamide and 2-thiophenacetyl chloride using Method A.

δ ppm (CDCl₃): 7.45 (dd, 1H, Ar-H), 7.23 (d, 1H, Ar-H), 7.07 (d, 1H, Ar-H), 6.96 (m, 3H, Ar-H), 6.05 (t, 1H, CH), 4.7 (m, 1H, CH), 2.75-4.1 (m, 10H, CH₂), 3.01 (m, 4H, CH₂), 2.03 (s, 3H, CH₃).

Compound No. 14: (S)-N-[[3-[3-Fluoro-4-[N-1[4-{2-thienyl(4-bromo)methyl}]-piperazinyl] phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

The title compound was made with (S)-N-[[3-[3[Fluoro-4-(N-1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl acetamide and 4-bromo-2-chloromethyl-thiophen using Method A.

δ ppm (CDCl₃) :7.44 (dd, 1H, Ar-H), 7.2-6.8 (m, 4H, Ar-H), 5.98 (t, 1H, Ar-H), 4.76 (m, 1H, CH), 4.02 (t, 1H, CH), 3.85-3.35 (m, 5H, CH₂), 3.1 (m, 4H, CH₂), 2.69 (m, 4H, CH₂), 2.03 (s, 3H, CH₃).

Method B:

Compound No. 15: (S)-N-[[3-[3-fluoro-4-[N-1-[4-{2-furyl-(5-nitro)methyl}]]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

To a suspension of (S)-N-[[3-[3[Fluoro-4-(N-1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl acetamide (770 mg, 2.29 mmol) in dichloromethane or THF (40 ml) in a round bottom flask (100 ml) filled with guard tube, was added molecular sieves (4A) followed by 5-nitro-2-furfural (420 mg, 2.98 mmol). The reaction mixture was stirred at 25°C for 1.5 hr. Sodium triacetoxy borohydride (1.93 g, 9.10 mmol) was then added to the reaction mixture. The whole reaction mixture was allowed to stir overnight at 25°C. TLC of the reaction mixture showed a faster moving spot compared to piperazine derivative. The reaction mixture was filtered through a Buckner funnel. It was washed with dichloromethane. Organic layer was washed with water, dried over sodium sulphate and solvent was removed to give crude product which was then purified by silica gel column using 2% methanol in

chloroform as eluent to afford the title compound 417 mg of m.p. 104-105°C.

δ ppm (CDCl₃) : 7.48 (d, 1H), 7.34 (m, 1H), 7.12 (d, 1H), 6.98 (t, 1H), 6.56 (d, 1H), 6.07 (bs, 1H), 4.81 (m, 1H), 4.07 (t, 1H), 3.69-3.53 (m, 5H) 3.16 (bs, 4H), 2.78 (bs, 4H), 2.07 (s, 3H).

5 **Compound No. 16: Hydrochloric salt of (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-nitro) methyl}] piperazinyl] phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide**

(S)-N-[[3-Fluoro-4-[N-1[4{2-furyl-(5-nitro)methyl}]piperazinyl]-phenyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide hydrochloride.

10 To an ethanolic solution of (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl-(5-nitro)-methyl}]piperazinyl] phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide (365 mg, 0.75 mmol in 7 ml of absolute ethanol) was added 0.30 ml of HCl in ethanol (2.6 N, 0.75 mmol) in cold (5°C) condition. The whole reaction mixture was stirred at 5-10°C for 2.0 hr. No change in TLC was observed.

15 Solvent was removed. The residue was digested with dichloromethane and the solid was crystallized from methanol isopropyl alcohol mixture to give the desired compound in 111 mg of 97% pure by HPLC. Mass : 461.8 (M+H⁺), 483.9 (M+Na⁺)

Compound No. 17: Citrate salt of (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-nitro)-methyl}]piperazinyl] phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide

20 Citrate salt of Compound No. 15 was made according to the method described for Compound No. 16 by using citric acid in molar proportions.

Compound No. 18: (S)-N[[3-[3-Fluoro-4-[N-1[4-(2-pyrrolylmethyl)]piperazinyl]-

phenyl]2-oxo-5-oxazolidinyl] methyl]acetamide

The title compound was made with (S)-N-[[3-[3[Fluoro-4-(N-1-piperazinyl)-phenyl]-2-oxo-5-oxazolidinyl]methyl acetamide and 2-pyrrolicarboxaldehyde using Method B.

5 δppm (CDCl₃): 8.76(br s, 1H, NH), 7.38(d, 1H, Ar-H), 7.04(d, 1H, Ar-H), 6.91(t, 1H, Ar-H), 6.77(s, 1H, Ar-H), 6.11(m, 3H, Ar-H, NH), 4.75 (m, 1H, CH), 4.0(t, 1H, CH), 3.8-3.5(m, 5H, CH₂), 3.08(m, 4H, CH₂), 2.65(m, 4H, CH₂), 2.01(s, 3H, CH₃)

Compound No. 19: (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-thienyl(3-methyl)methyl}]-piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide

10 The title compound was made with (S)-N-[[3-[3[Fluoro-4-(N-1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl acetamide and 3-methyl-2-thiophenecarboxaldehyde using Method B.

15 δppm (CDCl₃) : 7.4(d, 1H, Ar-H), 7.15(d, 1H, Ar-H), 7.03(d, 1H, Ar-H), 6.92(t, 1H, Ar-H), 6.79(d, 1H, Ar-H), 6.07(t, 1H, NH), 4.75(m, 1H, CH), 3.98(t, 1H, CH), 3.55-3.95(m, 6H, CH₂), 3.09(m, 4H, CH₂), 2.69(m, 3H, CH₂), 2.22(s, 3H, CH₃), 2.01(s, 3H, CH₃)

Compound No. 20: (S)-N[[3-[3-Fluoro-4-[N-1[4-(3-furylmethyl)]piperazinyl]phenyl]2-oxo-5-oxazolidinyl] methyl]acetamide

20 The title compound was made with (S)-N-[[3-[3[Fluoro-4-(N-1-piperazinyl)-phenyl]-2-oxo-5-oxazolidinyl]methyl acetamide and 3-furaldehyde using Method B.

δ ppm (CDCl₃) : 7.42(m,3H, Ar-H), 7.04(d, 1H, Ar-H), 6.92(t,1H,Ar-H), 6.43(s,1H, Ar-H), 6.0(t, 1H, NH), 4.75(m,1H, CH), 4.01(t, 1H, CH), 3.8-3.5(m,3H,CH₂), 3.47(s,2H,CH₂), 3.1(m, 4H,CH₂), 2.66 (m,4H, CH₂), 2.01(s,3H, CH₃)

5 **Compound No. 21: (S)-N-[[3-[3-Fluoro-4-[N-1[4-{2-thienyl(5-methyl)methyl}]-piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide**

The title compound was made with (S)-N-[[3-[3[Fluoro-4-(N-1-piperazinyl)-phenyl]-2-oxo-5-oxazolidinyl]methyl acetamide and 5-methyl-2-thiophencarboxaldehyde using Method B.

10 δ ppm (CDCl₃) : 7.4(dd, 1H, Ar-H), 7.03(d, 1H, Ar-H), 6.92(t, 1H, Ar-H), 6.71(d, 1H, Ar-H), 6.58(d, 1H, Ar-H), 6.08(t, 1H, NH), 4.75(m,1H,CH), 3.98(t,1H,CH), 3.8-3.5(m,5H, CH₂), 3.07(m, 4H, CH₂), 2.65(m,4H,CH₂), 2.45(s,3H, CH₃), 2.01(s,3H,CH₃)

15 **Compound No. 22: (S)-N-[[3-[3-Fluoro-4-[N-1[4-{2-pyrrole(1-methyl)methyl}]-piperazinyl] phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide**

The title compound was made with (S)-N-[[3-[3[Fluoro-4-(N-1-piperazinyl)-phenyl]-2-oxo-5-oxazolidinyl]methyl acetamide and N-methyl-2-pyrrolocarboxaldehyde using Method B.

20 δ ppm (CDCl₃) :7.36(d, 1H, Ar-H), 7.04(d, 1H, Ar-H), 6.9(t,1H,Ar-H), 6.6(s, 1H,Ar-H), 6.02(s, 3H, Ar-H, NH), 4.73(m, 1H, CH), 4.0(t, 1H, CH), 3.8-3.5(m,6H, CH₂),3.49(s,2H, CH₂), 3.02(m,4H, CH₂), 2.58(m, 4H, CH₂). 2.01(s, 3H, CH₃)

Compound No. 23: (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-thienyl(5-nitro)methyl}]piperaziny]]phenyl]2-oxo-5-oxazolidinyl)methyl]acetamide

The title compound was made with (S)-N-[[3-[3[Fluoro-4-(N-1-piperaziny)]-phenyl]-2-oxo-5-oxazolidinyl)methyl acetamide and 5-nitro-2-thiophencarboxaldehyde using Method B.

δ ppm (CDCl₃): 7.80 (d, 1H, Ar-H), 7.45 (dd, 1H, Ar-H), 7.05 (d, 1H, Ar-H), 6.91 (m, 2H, Ar-H), 6.07 (t, 1H, NH), 4.76 (m, 1H, CH), 4.2-3.5 (m, 6H, CH₂), 3.11 (m, 4H, CH₂), 2.73 (m, 4H, CH₂), 2.02 (s, 3H, CH₃).

Compound No. 24: (S)-N[[3-[3-Fluoro-4-[N-1[4-[2-furyl{5-(N-thiomorpholinyl)-methyl}]methyl]piperaziny]]phenyl]2-oxo-5-oxazolidinyl)methyl]acetamide

The title compound was made with (S)-N-[[3-[3[Fluoro-4-(N-1-piperaziny)]-phenyl]-2-oxo-5-oxazolidinyl)methyl acetamide and 5-(N-thiomorpholinylmethyl)-2-furan- carboxaldehyde using Method B.

δ ppm (CDCl₃): 7.45 (d, 1H, Ar-H), 7.05 (d, 1H, Ar-H), 6.9 (t, 1H, Ar-H), 6.18 (d, 2H, Ar-H), 6.09 (m, 1H, NH), 4.76 (m, 1H, CH), 4.02 (t, 1H, CH), 3.35-3.9 (m, 7H, CH₂), 3.12 (m, 4H, CH₂), 2.75 (m, 11H, CH₂), 2.02 (s, 3H, CH₃).

Compound No. 25: (S)-N[[3-[3-Fluoro-4-[N-1[4-[2-furyl{5-(N-morpholinyl)-methyl}]methyl]]piperaziny]] phenyl]2-oxo-5-oxazolidinyl)methyl]acetamide

The title compound was made with (S)-N-[[3-[3[Fluoro-4-(N-1-piperaziny)]-phenyl]-2-oxo-5-oxazolidinyl)methyl acetamide and 5-(N-morpholinylmethyl)2-furancarboxaldehyde using Method B.

δ ppm (CDCl₃) :7.5-6.3 (m, 3H, Ar-H), 6.19 (d, 2H, Ar-H), 5.9 (m, 1H, NH), 4.7 (m, 1H, CH), 4.00 (t, 1H, CH), 3.3-3.8 (m, 10H, CH₂), 3.09 (m, 4H, CH₂), 2.69 (m, 4H, CH₂), 2.49 (m, 4H, CH₂), 2.01 (s, 3H, CH₃).

Compound No. 26: (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-acetoxymethyl)-methyl}]piperazinyl] phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

The title compound was made with (S)-N-[[3-[3[Fluoro-4-(N-1-piperazinyl)-phenyl]-2-oxo-5-oxazolidinyl]methyl acetamide and 5-(N-morpholinylmethyl)2-furylcarboxaldehyde using Method B.

δ ppm (CDCl₃) :7.42 (dd, 1H), 7.06 (dd, 1H), 6.95 (d, 1H), 6.35 (d, 1H), 6.22 (d s, 2H), 5.04 (s, 2H), 4.02 (bs, 4H, CH₂), 3.74 (t, 1H), 3.75- 3.6 (m, 3H), 3.64 (s, 3H) 3.10 (bs, 4H) 2.70 (bs, 4H), 2.06 (s, 3H), 2.02 (s, 3H).

Compound No. 27: (S)-N-[[3-Fluoro-4-[N-1[4-{2-thienyl(5-bromo)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

The title compound was made with (S)-N-[[3-[3[Fluoro-4-(N-1-piperazinyl)-phenyl]-2-oxo-5-oxazolidinyl]methyl acetamide and 5-acetoxy methyl -2-furan-carboxaldehyde by using Method A.

δ ppm (CDCl₃): 7.42 (dd, 1H, Ar-H), 7.04 (d, 1H, Ar-H), 6.88 (m, 2H, Ar-H), 6.69 (d, 1H, Ar-H), 6.00 (t, 1H, NH), 4.76 (m, 1H, CH), 4.01 (t, 1H, CH), 3.4-3.8 (m, 5H, CH₂), 3.07 (m, 4H, CH₂), 2.67 (m, 4H, CH₂).

Compound No. 28: (S)-N-[[3-Fluoro-4-[N-1[4-(5-nitro-2-furylmethyl)piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]dichloroacetamide

δ ppm (CDCl_3) : 7.41- 6.51(m, 6H), 5.96(s, 1H), 4.81(m,1H), 4.06(t, 1H), 3.77-3.66(m,5H), 3.11- 2.71(m,8H)

Method C:

5 **Compound No. 29: (S)-N-[[3-[3-Fluoro-4-[N-1[4-(5-nitro-2-thienoyl)]piperazinyl]-phenyl]2-oxo-5-oxazolidinyl)methyl]acetamide hydrochloride**

10 To (S)-N-[[3-[3[Fluoro-4-(N-1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]-methyl] acetamide (1.14 mmol) in DMF (10 mL) cooled to 5°C, 5-nitro-2-thienoic acid (0.16g, 0.95 mmol), N-methylmorpholine (0.12g, 1.14 mmol) and 1-hydroxybenzotriazole (0.17 g, 1 mmol) were added and the reaction mixture was stirred for 15 min. To it 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.18g, 0.95 mmol) was added and the reaction mixture was stirred for 18 hrs allowing it to warm to R.T. Then the reaction mixture was diluted with 25 mL water and extracted with EtOAc (3x25 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and evaporated in vacuo. 15 The residue was purified by column chromatography (3% MeOH/ CHCl_3) to yield 0.19g of product. This product was dissolved in dichloromethane (5 mL) and cooled to 5 C. To it 1 mL of satd. ethanolic-HCl solution was added and stirred for 15 min. Then the reaction mixture was evaporated, co-evaporated with ether and dried in vacuo to yied 0.19 g of final product.

20 δ ppm (DMSO) :8.2 (t,1H, Ar-H), 8.1(m,1H,Ar-H), 7.5(m,2H, Ar-H), 7.17(d,1H, Ar-H), 7.09(t,1H,Ar-H), 4.7(m,1H, CH), 4.08(t,1h, CH), 3.73(m,6H,CH₂), 3.05 (m, 5H, CH₂), 1.83(s, 3H, CH₃).

Compound No. 30: (S)-N-[[3-[3-Fluoro-4-[N-1[4-(2',2'-diphenyl-2'-hydroxy acetyl)]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

The title compound was made with (S)-N-[[3-[3[Fluoro-4-(N-1-piperazinyl)-phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide and 2,2 -diphenyl -2-hydroxy acetic acid using Method C.

EXAMPLE 2

Analogues of (S)-N-[[3-[3-Fluoro[4-[3-(1 α ,5 α ,6 α)-6-[N-methyl] amino]-3-azabicyclo [3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl] methyl]acetamide (Core II)

The heteroaromatic group with the corresponding appendage can be introduced on the nitrogen atom of ring C of compounds of Formula I by one of the methods described below:

Method A:

General procedure was same as described earlier (method A). Only the core amine of Formula V is (S)-N-[[3-[3-Fluoro[4-[3-(1 α ,5 α ,6 α)-6-[N-methyl]amino]-3-azabicyclo [3.1.0] hexane] phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide here.

Compound No. 31:(S)-N-[[3-[3-Fluoro[4-[3-(1 α ,5 α ,6 α)-6-[N-(5-nitro-2-furoyl)-N-methyl]amino]-3-azabicyclo-[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide

PREPARATION OF (S)-N-[[3-[3-Fluoro[4-[3-(1 α ,5 α ,6 α)-6-[N-methyl]amino]-3-azabicyclo [3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide (core II)

(a) PREPARATION OF 3-Fluoro[4-[3-(1 α ,5 α ,6 α)-6-[N-(tert butoxy carbonyl) amino]-3-azabicyclo- [3.1.0]hexane] nitrobenzene.

(1 α , 5 α , 6 α)-6-Amino-3-azabicyclo [3.1.0] hexane (7.0 g, 0.03535 mol) was taken in CH₃CN (50 mL) and diisopropyl ethyl amine (4.5606 g, 0.03535 mol) was added followed by 3,4-difluoro nitrobenzene (5.6212 g, 0.03535 mol) and heated at 70°C for 4 hrs. The reaction was monitored by the disappearance of the starting material on the TLC (eluent CHCl₃: MeOH (19:1)). The reaction mixture was concentrated under vacuum, triturated with H₂O, filtered, washed with hexane and dried to obtain the title compound. Yield: 10 g

δ ppm (CDCl₃) : 7.94-6.50 (m, 3H), 4.80 (s, 1H) 3.95--3.63 (m, 4H), 2.43 (s, 1H), 1.92 (s, 2H), 1.47 (s, 9H).

(b) PREPARATION OF 3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(tert butoxy carbonyl)-N-methyl]-amino]-3-azabicyclo- [3.1.0]hexane]nitrobenzene

3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(tert butoxy carbonyl)-amino]-3-azabicyclo- [3.1.0] hexane] nitro benzene (10g, 0.029 mol) was taken in 60 ml THF at 0°C. Sodium hydride (1.06 g, 0.045 mol) was added portion-wise over 5 min. After complete addition the reaction mixture was stirred for 30 min. at 0°C. Methyl iodide (8.42 g, 0.059 mol) was then added over 10 min. at 0°C followed by tert n-butyl ammonium iodide (1g). The reaction mixture was stirred for 4 hrs. The reaction mixture was then concentrated under vacuum. H₂O (50 mL) was added followed by extraction with dichloromethane (3 x 50 mL). The combined organic layer was dried over Na₂SO₄, filtered and concentrated to obtain the title compound. Yield: 10.25 g

δ ppm (MeOD): 7.91-6.47 (m, 3H), 3.89-3.61 (m, 4H) 2.8 (s, 3H), 2.34 (s, 1H), 1.96 (s, 2H), 1.46 (s, 9H).

(c) PREPARATION OF 3-Fluoro [4-{3-(1 α , 5 α , 6 α)-6-[N-(tert butoxy carbonyl)-N-methyl amino}-3-azabicyclo- [3.1.0] hexane] aniline.

3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(tert butoxy carbonyl)-N-methyl]-amino]-3-azabicyclo- [3.1.0]hexane]nitrobenzene (26 g, 0.074 mol) was taken in 75 mL THF and 75 mL MeOH. 10% Pd/C (dry) (3g) was added and the reaction mixture was shaken in a Parr hydrogenator at 40 psi for 3 hours. The reaction mixture was filtered through celite bed. The filtrate was concentrated to obtain the title compound. Yield: 21.2 g

δ ppm (CDCl₃) (MeOD): 6.55-6.33 (m, 3H), 3.54-3.00 (m, 4H) 2.87 (s, 3H), 2.55 (s, 1H), 1.96 (s, 2H) 1.40 (s, 9H).

(d) PREPARATION OF 3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(tert butoxy carbonyl)-N-methyl]amino]-3-azabicyclo- [3.1.0]hexane]benzyloxy carbamate

3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(tert-butoxy carbonyl)-N-methyl]amino]-3-azabicyclo [3.1.0] hexane] aniline (21g, 0.065 mol) was taken in THF (100 ml and cooled to -15°C. Sodium bicarbonate (27.47 g, 0.32 mol) was added followed by benzyl chloroformate (14.5 g, 0.055 mol) which was added slowly over 30 min. After complete addition the stirring was combined for the maintaining the temperature between 0-5°C. The reaction was monitored by the disappearance of the reaction mixture on TLC (eluent CHCl₃ : MeOH : 9:1). The reaction mixture was filtered and filtrate concentrated under vacuum. H₂O (20 ml) was added and extracted with CH₂Cl₂ (3x100 ml). The combined organic layer was dried over Na₂SO₄. This was filtered and the filtrate concentrated. The semisolid was triturated with MeOH. The solid was filtered to obtain the title compound.

δ ppm (CDCl_3) : 7.4:6.5 (m, 8H), 5.24 (s, 2H), 3.8-3.3(m, 4H), 2.92 (s, 3H), 2.61 (s, 1H), 1.90 (s, 2H), 1.54 (s, 9H, tBu).

(e) PREPARATION OF (S)-N-[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-(N-(tert butoxy carbonyl)-N-methyl]amino]-3- azabicyclo [3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]methyl alcohol.

3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-(N-(tert butoxy carbonyl)-N-methyl]amino]-3-azabicyclo [3.1.0]hexane]benzyloxy carbamate (21 g, 0.04615 mol) was taken in freshly distilled THF (200 mL). The system was thoroughly flushed with N_2 . The temperature was then brought down to -78°C in acetone dry ice. n-BuLi (59.13 mL of 15% solution in hexane, 0.13846 mol) was added over 30 min. maintaining the temperature at -78°C . The stirring was continued for 2.5 hours at -78°C . R(-) Glycidyl butyrate was added in one go and stirred at -78°C for further 1.5 hours. The temperature was gradually increased to rt. and stirred over night. 20% aqueous solution of NH_4Cl (200ml) was then added gradually added over 10 min. After 30 min. stirring, the organic layer was separated. The aqueous layer was further extracted with EtOAc (3 x 75 ml). The combined organic was dried over Na_2SO_4 , filtered and concentrated. The product was purified by silica gel column chromatography (100-200) eluent (2% MeOH: 98% CHCl_3) to yield 14 g.

δ ppm (CDCl_3) : 7.35-6.55 (m, 3H), 4.7 (m, 1H), 3.9-3.8 (m, 4H), 3.7-3.2 (m, 4H), 2.8 (s, 3H, N- CH_3), 2.5 (s, 1H), 1.8 (s, 2H), 1.47 (s, 9H).

(f) **PREPARATION of (S)-N-[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(tert butoxy carbonyl)-N-Methyl]amino]-3-azabicyclo[3.1.0]hexane]phenyl]-2-oxa-5-oxazolidinyl] methyl methanesulfonate.**

(S)-N-[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(tert butoxy carbonyl)-N-methyl]amino]-3-azabicyclo[3.1.0]hexane]phenyl]-2-oxa-5-oxazolidinyl]methyl

alcohol (16 g, 0.038 mol) was taken in 50 ml pyridine at 5-10°C and methane sulphonyl chloride (12.71 g, 0.14 mol) was added over 5 min. The stirring was continued for 4 hours. The progress of the reaction was monitored by the disappearance of the starting material on TLC (eluent 10% CHCl_3 : 10% MeOH). The reaction mixture was filtered, filtrates concentrated under vacuum, washed with H_2O (50 ml) and extracted with CH_2Cl_2 (3 x 75 mL). The combined organic layer was dried over Na_2SO_4 , filtered and filtrate concentrated. This was dried thoroughly under vacuum.

(g) **PREPARATION OF (S)-N-[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(tert butoxy carbonyl)-N-Methyl]amino]-3- azabicyclo[3.1.0]hexane]phenyl]-2-oxa-5-oxazolidinyl]methyl azide.**

(S)-N-[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(tert butoxy carbonyl)-N-methyl]amino]-3-azabicyclo [3.1.0] hexane]phenyl]-2-oxa-5-oxazolidinyl]methyl methane sulphonate (15 g, 0.03 mol) was taken in DMF (50 ml) and NaN_3 (9.76 g, 0.15 mol) was added and heated at 70°C for 4 hours. The progress of the reaction was monitored by the disappearance of the starting material on TLC. The reaction mixture was filtered. The filtrate was concentrated under vacuum. This was washed with H_2O and extracted EtOAc (3x75 ml). The combined organic layer was dried over Na_2SO_4 , filtered and concentrated to obtain the title compound. Yield 11.5 g.

δ ppm (CDCl_3) : 7.3-6.5 (m, 3H), 4.7 (m, 1H)

(h) PREPARATION OF (S)-N-[3-[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(tert butoxy carbonyl)-N-methyl]amino]-3-azabicyclo[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl] methyl amine

5 (S)-N-[3-[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(tert butoxy carbonyl)-N-methyl]amino]-3-azabicyclo[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]methyl azide (11.3 g, 0.026 mol) was taken in 75 ml MeOH and 75 ml EtOAc and 10% Pd/C was added. The reaction mixture was shaken at 50 psi for 6 hrs. The progress of the reaction was monitored by the disappearance of the starting material on the TLC. The
10 reaction mixture was filtered through a celite bed. The filtrate was concentrated. The product was triturated with diethyl ether. The solid was filtered, to obtain the title compound. Yield - 7.6 g.

(i) PREPARATION OF (S)-N-[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(tert butoxy carbonyl)-N-Methyl]amino]-3- azabicyclo[3.1.0]hexane]phenyl]-2-oxa-5-oxazolidinyl]acetamide.

15 (S)-N-[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(tert butoxy carbonyl)-N-methyl]amino]-3-azabicyclo[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]methyl amine (7.6g, 0.018 mol) was taken in pyridine (8 ml), CH_2Cl_2 (50 mL) and acetic anhydride (2.214 g, 0.0217 mol) at 0-10°C. The reaction mixture was stirred and the
20 progress of the reaction was monitored by the disappearance of the starting material on the TLC eluent (CHCl_3 : MeOH :: 9:1). The reaction mixture was concentrated under vacuum. The concentrate was washed with H_2O (50 mL) and extracted with CH_2Cl_2 (3x50 mL). The combined organic layer was dried over Na_2SO_4 , filtered and

concentrated. This product was triturated with diethyl ether, filtered and dried to yield the little compound. Yield: 6.6 g.

δ ppm (CDCl_3) : 7.33-6.56 (m, 3H), 6.19 (t, 1H), 4.73 (m, 1H), 3.98 (t, 1H), 3.77-3.2 (m, 7H) 2.8 (s, 3H), 2.52 (s, 1H), 2.0 (s, 3H), 1.96 (s, 2H), 1.48 (s, 9H).

5 **(j) PREPARATION OF (S)-N-[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-Methyl]amino]-3-azabicyclo[3.1.0]hexane]phenyl]-2-oxa-5-oxazolidinyl] acetamide.**

(S)-N-[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(tert butoxy carbonyl)-N-Methyl]amino]-3-azabicyclo[3.1.0]hexane]phenyl]-2-oxa-5-oxazolidinyl]acetamide
10 (1g) was taken in CH_2Cl_2 (50mL) at 0°C and CF_3COOH (10 mL) was added and stirred for 4h. The reaction mixture was concentrated under vacuum. The residue was dissolved in EtOAc and neutralised with solid NaHCO_3 . The EtOAc layer was filtered and the filtrate was concentrated to obtain the title compound.

Compound No. 31: (S)-N-[[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(5-nitro-2-furoyl)-N-methyl]amino]-3-azabicyclo-[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide
15

The title compound was made using (S)-N-[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-Methyl]amino]-3-azabicyclo[3.1.0]hexane]phenyl]-2-oxa-5-oxazolidinyl]acetamide and 5-nitro-furoyl chloride using Method A.

20 δ ppm (CDCl_3) : 7.7-6.0 (m, 6H), 4.74 (m, 1H), 4.0-2.9 (m, 11H), 2.43 (s, 2H), 2.01 (s, 3H), 1.62 (s, 1H), 1.91 (s, 2H)

Compound No. 32: (S)-N-[[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(3-furoyl)-N-methyl]amino]-3-azabicyclo-[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide

5 The title compound was made using (S)-N-[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-methyl]amino]-3-azabicyclo[3.1.0]hexane]phenyl]-2-oxa-5-oxazolidinyl]acetamide and furan-3-carboxyaldehyde using Method B.

Compound No. 71: (S)-N-[[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(2-thiopheneacetyl)-N-methyl]amino]-3-azabicyclo-[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide

10 The title compound was made using (S)-N-[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-methyl]amino]-3-azabicyclo[3.1.0]hexane]phenyl]-2-oxa-5-oxazolidinyl]acetamide and 2-thiopheneacetyl chloride using Method A.

Compound No. 72: (S)-N-[[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(5-formyl-2-furylmethyl)-N-methyl]amino]-3-azabicyclo-[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl] methyl]acetamide

15

The title compound was made using (S)-N-[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-Methyl]amino]-3-azabicyclo[3.1.0]hexane]phenyl]-2-oxa-5-oxazolidinyl]acetamide and 5-formyl-2-furylmethyl chloride using Method A.

Compound No. 73: (S)-N-[[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(3-thienoyl)-N-methyl]amino]-3-azabicyclo-[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl] methyl]acetamide

20

The title compound was made using (S)-N-[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-Methyl]amino]-3-azabicyclo[3.1.0]hexane]phenyl]-2-oxa-5-oxazolidinyl]acetamide and 3-chlorothiophenyl chloride using Method A.

Compound No. 33: (S)-N-[[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(5-bromo-2-furoyl)-N-methyl]amino]-3-azabicyclo[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl] methyl]acetamide

The title compound was made using (S)-N-[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-Methyl]amino]-3-azabicyclo[3.1.0]hexane]phenyl]-2-oxa-5-oxazolidinyl]acetamide and 5-bromo 2-furoyl chloride using Method A.

Method B:

General procedure was same as described earlier in section 7.1.1.2. (Method B) described earlier for example Rbx-6247. Only the core amine of Formula V is (S)-N-[[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-methyl]amino]-3-azabicyclo[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide here.

Compound No. 34: (S)-N-[[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(5-nitro-2-thienyl)-methyl]-N-methyl]amino]-3-azabicyclo[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

The title compound was made using (S)-N-[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-methyl]amino]-3-azabicyclo[3.1.0]hexane]phenyl]-2-oxa-5-oxazolidinyl]acetamide and 5-nitro-thiophene-2-carboxyaldehyde using Method B.

Compound No. 35: (S)-N-[[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(5-nitro-2-furylmethyl)-N-methyl]amino]-3-azabicyclo[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

5 The title compound was made using (S)-N-[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-Methyl]amino]-3-azabicyclo[3.1.0]hexane]phenyl]-2-oxa-5-oxazolidinyl]acetamide and 5-nitro-furan-2-carboxyaldehyde using Method B.

Analogues of (S)-N-[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(tert butoxy carbonyl)-N-Methyl]amino methyl]-3-azabicyclo[3.1.0]hexane]phenyl]-2-oxa-5-oxazolidinyl]acetamide (core III).

10 The heteroaromatic group with the corresponding appendage can be introduced on the nitrogen atom of ring C of compounds of Formula I by one of the methods described below:

Method A:

15 General procedure was same as described earlier in section 7.1.1.1 (Method A) described earlier for example Rbx-6408. Only the core amine of Formula V is (S)-N-[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(tert butoxy carbonyl)-N-Methyl]amino methyl]-3- azabicyclo[3.1.0]hexane]phenyl]-2-oxa-5-oxazolidinyl] acetamide (core III).

20 **Compound No. 36:** (S)-N-[[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(5-formyl-2-furylmethyl)-N-methyl]aminomethyl]-3-azabicyclo[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

(a) PREPARATION OF 3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(tert butoxy carbonyl)-aminomethyl]-3-azabicyclo- [3.1.0]hexane] nitrobenzene.

(1 α , 5 α , 6 α)-6-Aminomethyl-3-azabicyclo [3.1.0] hexane (7.0 g, 0.03535 MH) was taken in CH₃CN 50 mL and diisopropyl ethyl amine (4.5606 g, 0.03535 mol) was added followed by 3,4-difluoro nitrobenzene (5.6212 g, 0.03535 mol) and heated at 70°C for 4 hrs. The reaction was monitored by the disappearance of the starting material on the (eluent CHCl₃ (19): MeOH (1). The reaction mixture was concentrated under vacuum, triturated with H₂O, filtered, washed with hexane and dried to obtain the title compound.

(b) PREPARATION OF 3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(tert butoxy carbonyl)-N-Methyl]-aminomethyl]-3-azabicyclo- [3.1.0]hexane]nitrobenzene

3-Fluoro [4-[3-(1 α , 5 α , 6 α)-6-[N-(tert butoxy carbonyl)-N-methyl]-aminomethyl]-3- azabicyclo- [3.1.0]hexane] nitrobenzene (10g, 0.029) was taken in 60 ml THF at 0°C. Sodium hydride (1.06 g, 0.045 mol) was added portion-wise over 5 min. after complete addition the reaction mixture was stirred for 30 min. at 0°C. Methyl iodide (8.42 g, 0.059 mol) was then added over 10 min. at 0°C followed by tert n-butyl ammonium iodide (1g). The reaction mixture was stirred for 4 hrs.. The reaction mixture was then concentrated under vacuum. H₂O (50 mL) was added followed by extraction with CH₂Cl₂ (3 x 50 mL). The combined organic layer was dried over Na₂SO₄, filtered and concentrated to obtain the title compound.

(c) PREPARATION OF 3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(tert butoxy carbonyl)-Nethyl] -aminomethyl] -3-azabicyclo- [3.1.0]hexane]aniline

3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(tert butoxy carbonyl)-N-Methyl]-aminomethyl]-3-azabicyclo-[3.1.0]hexane]nitro benzene (26 g, 0.074 mol) was taken in 75 mL THF and 75 mL MeOH. 10% Pd/ dry (3g) was taken in 75 ml THF and 75 mL MeOH. 10% Pd/C dry (3g) was added and the reaction mixture was shaken in a parr hydrogenator at 40 for 3 hours. The reaction mixture was filtered through celite led. The filtrate was concentrated to obtain the title compound.

(d) PREPARATION OF 3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(tert butoxycarbonyl)-N-methyl]amino]-3-azabicycl-[3.1.0]hexane]benzyloxy carba-
mate

3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(tert-butoxy carbonyl)-N-methyl]amino-methyl]-3-azabicyclo [3.1.0] hexane] aniline (21g, 0.065 mol) was taken in THF (100 ml and cooled to -15°C. Sodium bicarbonate (27.47 g, 0.32 mol) was added followed by benzyl chloroformate (14.5 g, 0.055 mol) which was added slowly over 30 min. after complete addition the stirring was combined for the maintaining the temperature between 0-5°C. The reaction was monitored by the disappearance of the reaction mixture on TLC (eluent CHCl₃ : MeOH : 9:1). The reaction mixture was filtered and filtrate concentrated under vacuum. H₂O (20 ml) was added and extracted with CH₂Cl₂ (3x100 ml). The combined organic layer was dried over Na₂SO₄. This was filtered, filtrate concentrated. The semisolid was triturated with MeOH. The solid was filtered to obtain the title compound.

(e) PREPARATION OF (S)-N-[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-N-(tert butoxy carboxy-N-methyl]amino methyl]-3- azabicyclo [3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl)methyl alcohol.

3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-(N-(tert butoxy carbonyl)-N-methyl]aminomethyl]-3-azabicyclo [3.1.0]hexane]benzyloxy carbamate (21 g, 0.04615 mol) was taken in freshly distilled THF (200 mL). The system was thoroughly flushed with N₂. The temperature was then brought down to -78°C in acetone dry ice. n-BuLi (59.13 mL of 15% solution in hexane, 0.13846 mol) was added over 30 min. maintaining the temperature at -78°C. The stirring was continued for 2.5 hours at -78°C. R(-) Glycidyl butyrate was added in one go and stirred at -78°C for further 1.5 hours. The temperature was gradually increased to rt. and stirred over night. 20% Solution of NH₄Cl (200ml) was then added gradually added over 10 min. after 30 min. stirring, the organic layer was separated. The aqueous layer was further extracted with EtOAc (3 x 75 ml). The combined organic was dried over Na₂SO₄, filtered and concentrated. The product was purified by silica gel column chromatography (100-200) eluent (2% MeOH: 98% CHCl₃) to yield 14 g.

(f) PREPARATION OF (S)-N-[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)- [N-(tert butoxy carbonyl)-N-methyl]aminomethyl]-3- azabicyclo[3.1.0]hexane]-phenyl]-2-oxa-5-oxazolidinyl] methyl methanesulfonate.

(S)-N-[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(tert butoxy carbonyl)-N-methyl]aminomethyl]-3-azabicyclo[3.1.0]hexane]phenyl]-2-oxa-5-oxazolidinyl]methyl alcohol (16 g, 0.038 mol) was taken in 50 ml pyridine at 5-10°C and methane sulphonyl chloride (12.71 g, 0.14 mol) was added over 5 min. The stirring was continued for 4 hours. The progress of the reaction was monitored by the disappearance of the starting material on TLC (eluent 10% CHCl₃ : 10% MeOH). The reaction mixture was filtered, concentrated under vacuum, washed with H₂O (50

ml) and extracted with CH_2Cl_2 (3 x 75 mL). The combined organic layer was dried over Na_2SO_4 , filtered and filtrate concentrated. This was dried thoroughly under vacuum.

5 **(g) PREPARATION OF (S)-N-[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(tert butoxy carbonyl)-N-Methyl]amino methyl]-3- azabicyclo[3.1.0]hexane]-phenyl]-2-oxa-5-oxazolidinyl]methyl azide.**

(S)-N-[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)- [N-(tert butoxy carbonyl)-N-methyl]aminomethyl]-3-azabicyclo[3.1.0]hexane]phenyl]-2-oxa-5-oxazolidinyl]methyl methane sulphonate (15 g, 0.03 mol) was taken in DMF (50 ml) and NaN_3 (9.76 g, 0.15 mol) was added and heated at 70°C for 4 hours. The progress of the reaction was monitored by the disappearance of the starting material on TLC. The reaction mixture was filtered. The filtrate was concentrated under vacuum. This was washed with H_2O and extracted EtOAc (3x75 ml). The combined organic layer was dried over Na_2SO_4 , filtered and concentrated to obtain the title compound. Yield: 11.5 g.

15 **(h) PREPARATION OF (S)-N-[3-[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(tert butoxy carbonyl)-N-methyl]aminomethyl]-3-azabicyclo[3.1.0]hexane]-phenyl]-2-oxo-5-oxazolidinyl] methyl amine**

(S)-N-[3-[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(tert butoxy carbonyl)-N-methyl]aminomethyl]-3-azabicyclo[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]methyl azide (11.3 g, 0.026 mol) was taken in 75 ml MeOH and 75 ml EtOAc and 10% Pd/C was added. The reaction mixture was shaken at 50 psi for 6 hrs. The progress of the reaction was monitored by the disappearance of the starting material on the TLC. The reaction mixture was filtered through a celite bed. The filtrate was

concentrated. The product was triturated with diethyl ether. The solid was filtered, to obtain the title compound. Yield - 7.6 g.

(i) **PREPARATION OF (S)-N-[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(tert butoxy carbonyl)-N-Methyl]amino methyl]-3- azabicyclo[3.1.0]hexane]-phenyl]-2-oxa-5-oxazolidinyl] acetamide.**

(S)-N-[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(tert butoxy carbonyl)-N-methyl]aminomethyl]-3-azabicyclo[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]methyl amine (7.6g, 0.018 mol) was taken in pyridine (8 ml), CH₂Cl₂ (50 mL) and acetic anhydride (2.214 g, 0.0217 mol) at 0-10°C. The reaction mixture was stirred and the progress of the reaction was monitored by the disappearance of the starting material on the TLC eluent (CHCl₃ : MeOH :: 9:1). The reaction mixture was concentrated under vacuum. The reaction mixture was washed with H₂O (50 mL) and extracted with CH₂Cl₂ (3x50 mL). The combined organic layer was dried over Na₂SO₄, filtered and concentrated. This product was triturated with diethyl ether, filtered and dried to yield the little compound. Yield - 6.6 g.

(j) **PREPARATION OF (S)-N-[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-methyl]aminomethyl]-3- azabicyclo[3.1.0]hexane]phenyl]-2-oxa-5-oxazolidinyl] acetamide.**

(S)-N-[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(tert butoxy carbonyl)-N-Methyl]amino]-3-azabicyclo[3.1.0]hexane]phenyl]-2-oxa-5-oxazolidinyl]acetamide (1g) was taken in CH₂Cl₂ (50mL) at 0°C and CF₃COOH(10 mL) was added and stirred for 4h. The reaction mixture was concentrated under vacuum. The residue was dissolved in EtOAc and neutralised with solid NaHCO₃. The EtOAc layer was filtered and the filtrate was concentrated to obtain the title compound.

(S)-N-[[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(5-formyl-2-furylmethyl)-N-methyl]aminomethyl]-3-azabicyclo-[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide

The title compound was made using (S)-N-[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-Methyl]aminomethyl]-3-azabicyclo[3.1.0]hexane]phenyl]-2-oxa-5-oxazolidinyl] acetamide and 5-formamido-2-furylmethylene chloride using Method A.

Compound No. 37: (S)-N-[[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(5-carboxyethyl-2-furylmethyl)-N-methyl]aminomethyl]-3-azabicyclo-[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl] methyl]acetamide

The title compound was made using (S)-N-[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-Methyl]aminomethyl]-3-azabicyclo[3.1.0]hexane]phenyl]-2-oxa-5-oxazolidinyl] acetamide and ethyl -5-(chloromethyl)-2-furan carboxylate using Method A.

Compound No. 38: (S)-N-[[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-(2-thiopheneacetyl)-N-methyl]aminomethyl]-3-azabicyclo-[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

The title compound was made using (S)-N-[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-Methyl]amino]-3-azabicyclo[3.1.0]hexane]phenyl]-2-oxa-5-oxazolidinyl]acetamide and 2-thiopheneacetyl chloride using Method A.

Method-B:

General procedure was same as described earlier in section 7.1.1.2. (Method B) described earlier. Only the core amine of Formula V is (S)-N-[3-[3-Fluoro[4-[3-

(1 α , 5 α , 6 α)-6-[N-Methyl]aminomethyl]-3-azabicyclo[3.1.0]hexane]phenyl]-2-oxa-5-oxazolidinyl] acetamide (core III)

Compound No. 39: (S)-N-[[3-[3-Fluoro[4-[3-(1 α ,5 α ,6 α)-6-[N-(5-nitro-2-thienyl-methyl)-N-methyl]aminomethyl]-3-azabicyclo-[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide

The title compound was made using (S)-N-[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-Methyl]aminomethyl]-3-azabicyclo[3.1.0]hexane]phenyl]-2-oxa-5-oxazolidinyl] acetamide and 5-nitro thiophene-2-carboxyaldehyde using Method B as in example rbx-6408.

Compound No. 40: (S)-N-[[3-[3-Fluoro[4-[3-(1 α ,5 α ,6 α)-6-[N-(5-nitro-2-furyl-methyl)-N-methyl] aminomethyl]-3-azabicyclo-[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide

The title compound was made using (S)-N-[3-[3-Fluoro[4-[3-(1 α , 5 α , 6 α)-6-[N-Methyl]aminomethyl]-3-azabicyclo[3.1.0]hexane]phenyl]-2-oxa-5-oxazolidinyl] acetamide and 5-nitro-furan-2-carboxyaldehyde using Method B.

Analogues of (S)-N-{3-[4-[4-N-methyl amino peperidin-1-yl]-3-fluoro-phenyl]-2-oxo-oxazolidin-5-yl]methyl acetamide (core IV).

The heteroaromatic group with the corresponding appendage can be introduced on the nitrogen atom of ring C of compounds of Formula I by one of the methods described below:

Method-A:

General procedure was same as described earlier (Method A). Only the amine of Formula V is (S)-N-{3-[4-[4-N-methyl amino piperidin-1-yl]-3-fluorophenyl]-2-oxo-oxazolidin-5-yl}methyl acetamide (core IV).

5 **Compound No. 74: Preparation of (S)-N-[[3-[4-[4-(N-methyl-N-2furyl(5-formyl)-methylaminopiperidine-1-yl]-3-fluorophenyl]-2-oxo-oxazolidin-5-yl]methyl]-acetamide.**

Preparation of (S)-N-{3-[4-[4-N-methyl amino piperidin-1-yl]-3-fluorophenyl]-2-oxo-oxazolidin-5-yl}methyl acetamide (core IV)

10 **(a) 1-[4(N-t-Butyloxycarbonylamino)piperidin-1-yl]-3-fluoro-nitrobenzene**

To a solution of difluoronitrobenzene (40g; 200 mmol) in acetonitrile (400 ml) was treated with ethyldiisopropyl amine (28.4 g; 219.72 mmol) and 4-(t-butyloxycarbonyl) amino piperidine (31.8g; 199 mmol). The whole reaction mixture was then heated at 60°C for 6.0 hr. The solution was cooled to ambient temperature and conc. in vacuo. The residue was dissolved in ethyl acetate and washed with water. Ethyl acetate layer was dried over anhydrous sodium sulphate. Solvent was removed to afford a yellow solid (60g).

20 δ ppm (CDCl₃) : 7.98-7.80 (m, 2H), 6.91 (t, J=9Hz, 1H) 4.53 (bs, 1H), 3.65 (d, J=12Hz, 3H) 2.98 (t, J=13Hz, 2H), 2.07 (m, 2H), 1.69-1.53 (m, 3H), 1.52 (s, 9H).

(b) 1-[4-(N-t-Butyloxy carbonyl N methyl)aminopiperidin-1-yl]-3-fluoro] nitrobenzene (B)

To a solution of intermediate A (89 mmol) in dry tetrahydrofuran (400 ml) was added sodium hydride (60%, 106 mmol) in cold condition (0°C) followed by tetrabutyl ammonium iodide (10 mmol). The reaction mixture was stirred at cold to r.t. for 2.0 hr. Methyl iodide (267 mmol) was then added at 0°C. Reaction mixture was stirred at r.t. for 12 hr. A faster moving spot was appeared. Excess sodium hydride was decomposed with water. Tetrahydrofuran was removed. The residue was dissolved in ethyl acetate, washed with water, brine and then with water. Organic layer was dried over anhydrous sodium sulphate and solvent was removed. A yellow solid (32g) was obtained.

δ ppm (CDCl₃) : 6.81 (t, J=12Hz, 1H) 6.44-6.37 (m, 2H), 4.70 (bs, 1H) 2.91 (d, J=12H, 2H), 2.78 (s, 3H), 2.72-2.65 (m, 2H), 1.47 (s, 9H).

(c) 1-[4-[(N-t-butyloxycarbonyl-N-methyl)amino-piperidin-1-yl]-3-fluoro]aniline (C)

A mixture of nitro compound B, (32.0g), 3.2 g of 10% palladium on carbon in 75 ml of methanol was shaken in a Paar shaker flask under 40 Psi hydrogen for 6.0 hr. TLC showed a slower moving spot. The reaction mixture was filtered through celite. Solvent was removed. A dark solid was obtained (28.6 g), it was subjected to next step without further characterisation.

(d) 1-{N-Carbobenzyloxy-[4-[(N-t-butyloxy carbonyl-N-methyl)-piperidin-1-yl]]-3-fluoro] aniline (D)

To the solution of aniline derivative C (19.0 g, 58.823 mmol) in dry tetrahydrofuran (150 ml) was added. Sodium hydrogen carbonate (19.76 g, 235.29 mmol). It was cooled to 0°C and benzyl chloroformate (12.9 ml, 50% toluene sol.) was added. The whole reaction mixture was stirred at 0°C-r.t. for 6.0 hr. TLC showed faster moving spot compare to aniline derivative. Reaction mixture was filtered through celite. Solvent removed. Residue was digested with hexane and solvent was removed to give 23.4g of CBz derivative.

10 δ ppm (CDCl₃) : 7.39-7.28 (m,6H), 6.99-6.86 (m,2H), 6.75 (bs, 1H), 5.20 (s, 2H), 4.20 (bs, 1H), 3.43 (d, J=12Hz, 2H), 2.79 (s, 3H), 2.71 (m, 2H), 1.97-1.86 (m, 2H), 1.49 (s, 9H)

(e) (S)-N-{3-[4-[4-(N-methyl-N-t-butyloxy carbonyl)amino-piperidin-1-yl]-3-fluorophenyl]-2-oxo-oxazolidin-5-yl]methanol (E)

15 To a solution (200 ml) of CBz derivative in (D; 24.0g, 52.516 mmol) dry tetrahydrofuran was added. BuLi (67 ml, 157 mmol) at -78°C under N₂. The reaction mixture was stirred at -78°C for 2.0 hr. Glycidyl butyrate (9.07g, 62.98 mmol)was then added to the reaction mixture at -78°C. It was stirred at -78°C for 1 hr. then allowed to reach r.t. TLC of the reaction mixture showed a slower moving spot.
20 Ammonium chloride (30ml) was added to the reaction mixture. It was stirred for 5 min. Ammonium chloride layer was separated and extracted with ethyl acetate. Tetrahydrofuran and ethyl acetate layer were combined, dried over anhydrous sodium sulphate. Solvent was removed. The residue was purified by column chromatography using CHCl₃ : MeOH (1.5%-2.5%) as eluent to give 10g of desired alcohol.

δ ppm (CDCl_3) : 7.46 (d, $J=8.0$ Hz, 1H), 7.10 (d, $J=9$ Hz, 1H), 6.94 (t, $J=9$ Hz, 1H) 4.55 (bs, 1H), 4.07-3.87 (m, 5H), 3.74 (bs, 1H), 3.46 (bs, 1H), 3.42 (bs, 1H), 2.78-2.89 (m, 5H), 1.96-1.85 (m, 2H), 1.72 (s, 1H), 1.47 (s, 9H).

(f) (S)-N-{3-[4-[4-(N-Methyl-N-t-butyloxy carbonyl)aminopiperidin-1-yl]-3-fluorophenyl]-2-oxo-oxazolidine-5-yl}methyl methane sulfonate (F)

To a solution of hydroxymethyl compounds (E, 24g, 56.73 mmol) in dichloromethane (400 ml) was added triethylamine (11.46 g, 113.46 mmol) followed by methane sulphonyl chloride at 0°C . The reaction mixture was stirred at 0°C - r.t. for 3.0 hr. TLC of the reaction mixture showed a faster moving spot. The reaction mixture was poured in to water and extracted with dichloromethane, washed with saturated sodium bicarbonate solution and then with water. Organic layer was dried over anhydrous sodium sulphate and solvent was removed to give 28.4g of compound (F).

δ ppm (CDCl_3) : 7.45 (d, $J=12$ Hz, 1H), 7.10-7.01 (m, 2H), 4.92 (bs, 1H), 4.53-4.40 (m, 2H), 4.12(t, $J=9$ Hz, 1H), 7.10-7.01 (m, 2H), 4.12 (t, $J=9$ Hz, 1H), 3.94-3.89 (m, 1H), 3.48 (d, $J=12$ Hz, 2H), 3.15 (m, 1H), 3.11 (s, 3H) 2.79 (s, 3H), 1.97-1.93 (m, 2H), 1.77-1.69 (m, 4H), 1.48 (s, 9H).

(g) (S)-N-{3-[4-[4-(N-Methyl-N-t-butyloxy carbonyl)aminopiperidin-1-yl]-3-fluorophenyl]-3-fluorophenyl]-2-oxo-oxazolidin-5-yl}methyl azide (G)

To the solution of mesyl derivative (F, 28.4 g, 56.68 mmol) in dimethyl formamide (350 ml) was added sodium azide (11.059, 70.05 mmol). The whole reaction mixture was heated at 80°C for 9.0 hr. TLC showed a faster moving spot.

Reaction mixture was filtered. Dimethyl formamide was removed in reduced pressure. The residue was digested in hexan to afford desired azide in 26.0 g.

δ ppm (CDCl_3) : 7.44 (d, 12Hz, 1H), 7.11 (bs, 1H), 6.97 (t, $J=9\text{Hz}$, 1H) 4.78 (bs, 1H), 4.09-3.49 (m, 7H), 2.90 (s, 3H), 2.75 (bs, 2H) 1.49 (s, 9H).

5 **(h) (S)-N-{3-[4-[4-(N-Methyl-N-t-butyloxy carbonyl)aminopiperidin-1-yl]-3-fluorophenyl]-2-oxo-oxazolidin-5-yl} methyl amine (H).**

To the solution of azido compound (G, 25.5g, 56.92 mmol) in methanol (50 ml) was added, 10% Pd/c (2.5 g). The whole reaction mixture was hydrgogenated for 10 hr. at 40 Psi. TLC showed a slower moving spot. It was filtered through celite bed
10 and solvent was removed to give desired product of 24.5 g.

δ ppm (CDCl_3) : : 7.45 (d, $J=12\text{Hz}$, 1H), 7.11 (d, $J=9\text{Hz}$, 1H), 6.94 (t, $J=9\text{Hz}$, 1H) 4.66 (bs, 1H), 4.00 (t, $J=9\text{Hz}$, 1H), 3.81 (t, $J=9\text{Hz}$, 1H), 3.45 (d, $J=9\text{Hz}$, 2H) 3.10-2.90 (m, 1H), 2.78 (3 3H), 2.73 (bs, 1H), 1.48 (s, 9H).

15 **(i) (S)-N-{3-[4-[4-(N-Methyl, N-1-butyloxy carbonyl) amino piperidin-1-yl]-3-fluorophenyl]-2-oxo-oxazolidin-5-yl}methyl acetamide.(I)**

To a solution of methyl amino derivative (7.0g, 16.58 mmol) in dichloro methane (120 ml) was added triethyl amine (2.18g; 21.58 mmol) reaction mixture was cooled to 0°C and acetic anhydride was added slowly. It was stirred at 0°-r.t. for 5.0 hr. TLC showed a faster moving spot. Reaction mixture was poured into water and
20 extracted with dichloromethane. Organic layer was washed with sodium bicarbonate, brine and water. Organic layer was dried over anhydrous sodium sulphate and solvent was removed to give 7.1 g of crude desired product which on purification gave 4.1 g of pure product.

δ ppm (CDCl_3) :7.43 (d, $J=12\text{Hz}$, 1H), 7.07 (d, $J=9\text{Hz}$, 1H), 6.95 (t, $J=9\text{Hz}$, 1H) 6.28 (bs, 1H), 4.00 (t, $J=9\text{Hz}$, 1H), 3.78-3.62 (m, 3H), 3.47 (d, $J=9\text{Hz}$, 2H) 2.80 (s, 3H), 2.75-2.71 (m 2H), 2.03 (s, 3H), 1.49 (s, 9H).

(j) (S)-N-[3-[4-[4-N-methylamino piperidin-1-yl]-3-fluorophenyl]-2-oxo-oxazolidin-5-yl] methyl acetamide.(J)

To a solution of Boc protected compound (I, 2.0 g, 4.31 mmol) in dichloromethane (35 ml) was added trifluoroacetic acid (5 ml) at 0°C . The whole reaction mixture was stirred at 0° r.t. for 3 hr. TLC of the reaction mixture showed a slower moving spot. Solvent was removed and the residue was dissolved in acetone, anhydrous pot. Carbonate was added to neutralize trifluoro acetic acid. It was stirred at r.t. for 2.0 min. then filtered through a Buckner funnel. Solvent was removed and the title compound was obtained. Yield: 1.5g

Compound No. 41: (S)-N-[[3-[4-[4-(N-methyl-N-2furyl(5formyl)methyl-aminopiperidine-1-yl]-3-fluorophenyl]-2oxo-oxazolidin-5-yl]methyl]acetamide

The title compound was made using (S)-N-[[3-[4-[4-(N-methyl-)amino piperidine-1-yl]-3-fluorophenyl]-2oxo-oxazolidin-5-yl]methyl]acetamide and 5-chloromethyl -2- furfural following Method A.

Compound No. 42: (S)-N-[[3-[4-[4-(N-methyl-N-(3,5-difluorobenzoyl)amino-piperidine-1-yl]-3-fluorophenyl]-2oxo-oxazolidin-5-yl] methyl]acetamide.

The title compound was made using (S)-N-[[3-[4-[4-(N-methyl-)amino piperidine-1-yl]-3-fluorophenyl]-2oxo-oxazolidin-5-yl]methyl]acetamide and 3,5-difluoro benzoyl chloride following Method A.

Compound No. 43: (S)-N-[[3-[4-[4-(N-methyl-N-(5-bromo-2-furoyl)amino-piperidine-1-yl]-3-fluorophenyl]-2oxo-oxazolidin-5-yl] methyl]acetamide

The title compound was made using (S)-N-[[3-[4-[4-(N-methyl-)amino piperidine-1-yl]-3-fluorophenyl]-2oxo-oxazolidin-5-yl]methyl]acetamide and 5-bromo-2-furoyl chloride following Method A.

Compound No. 44: (S)-N-[[3-[4-[4-(N-methyl-N-(5-nitro-2-furoyl)amino-piperidine-1-yl]-3-fluorophenyl]-2oxo-oxazolidin-5-yl]methyl]acetamide.

The title compound was made using (S)-N-[[3-[4-[4-(N-methyl-)amino piperidine-1-yl]-3-fluorophenyl]-2oxo-oxazolidin-5-yl]methyl]acetamide and 5-nitro-2-furoyl chloride following Method A.

Compound No. 45: (S)-N-[[3-[4-[4-(N-methyl-N—3-furoyl)aminopiperidine-1-yl]-3-fluorophenyl]-2oxo-oxazolidin-5-yl]methyl]acetamide.

The title compound was made using (S)-N-[[3-[4-[4-(N-methyl-)amino piperidine-1-yl]-3-fluorophenyl]-2oxo-oxazolidin-5-yl]methyl]acetamide and 3-furoyl chloride using Method A.

Compound No. 46: (S)-N-{3-[4-[4-(N-methyl, N- 2-furoyl)aminopiperidine-1-yl]-3-fluorophenyl]-2oxo-oxazolidin-5-yl methyl]acetamide.

The title compound was made using (S)-N-[[3-[4-[4-(N-methyl-)amino piperidine-1-yl]-3-fluorophenyl]-2oxo-oxazolidin-5-yl]methyl]acetamide and 2-furoyl chloride following Method A.

Compound No. 47: (S)-N-{3-[4-[4-(N-methyl,2-thiopheneacetyl)aminopiperidine-1-yl]-3-fluorophenyl]-2oxo-oxazolidin-5-yl methyl]acetamide.

The title compound was made using (S)-N-[[3-[4-[4-(N-methyl-)amino piperidine-1-yl]-3-fluorophenyl]-2oxo-oxazolidin-5-yl]methyl]acetamide and 2-thio-
5 phenyl acetylchloride chloride following Method A.

Method-B:

General procedure was same as described earlier in section (Method B), only the amine of Formula V is (S)-N-[[3-[4-[4-(N-methyl-)amino piperidine-1-yl]-3-fluorophenyl]-2oxo-oxazolidin-5-yl]methyl]acetamide (core IV).

Compound No. 48: (S)-N-[[3-[4-[4-(N-methyl-N-2furylmethyl) aminopiperidine-1-yl]-3-fluorophenyl]-2oxo-oxazolidin-5-yl]methyl]acetamide.

The title compound was made using (S)-N-[[3-[4-[4-(N-methyl-)amino piperidine-1-yl]-3-fluorophenyl]-2oxo-oxazolidin-5-yl]methyl]acetamide and furan-2-carboxaldehyde following Method B.

Compound No. 49: (S)-N-[[3-[4-[4-(N-methyl-N-3-furyl)aminopiperidine-1-yl]-3-fluorophenyl]-2oxo-oxazolidin-5-yl] methyl]acetamide.

The title compound was made using (S)-N-[[3-[4-[4-(N-methyl-)amino piperidine-1-yl]-3-fluorophenyl]-2oxo-oxazolidin-5-yl]methyl]acetamide and furan-3-carboxaldehyde following METHOD B.

Compound No. 50: (S)-N-[[3-[4-[4-(N-methyl-N-2-furyl(5-nitro)methyl)-aminopiperidine-1-yl]-3-fluorophenyl]-2oxo-oxazolidin-5-yl] methyl]acetamide.

The title compound was made using (S)-N-[[3-[4-[4-(N-methyl-)amino piperidine-1-yl]-3-fluorophenyl]-2oxo-oxazolidin-5-yl]methyl]acetamide and 5- nitro furan -2- carboxaldehyde using Method B.

5 δ ppm (CDCl₃) : 7.40(d, 1H), 7.29 (m, 1H), 7.29 (m, 1H), 7.05 (dd, 1H), 6.92 (t, 1H), 6.48 (d, 1H), 6.26 (bs, 1H), 4.76 (bs, 1H), 4.01 (t, 1H), 3.77-3.60 (m, 5H), 3.47 (d, 2H), 2.66 (t, 3H), 6.26 (bs, 1H), 4.76 (bs, 1H), 4.01 (t, 1H), 3.77-3.60 (m, 5H), 3.47 (d, 2H), 2.66 (t, 3H), 6.26 (bs, 1H), 4.76 (bs, 1H), 4.01 (t, 1H), 3.77-3.60 (m, 5H), 3.47 (d, 2H), 2.66 (5, 3H), 2.37 (s, 3H), 2.01 (s, 3H), 1.93-1.25 (m, 4H).

10 **Compound No. 51:** (S)-N-[[3-[4-[4-(N-methyl-N-2-thienyl(5-nitro)methyl)-aminopiperidine-1-yl]-3-fluorophenyl]-2oxo-oxazolidin-5-yl] methyl]acetamide.

The title compound was made using (S)-N-[[3-[4-[4-(N-methyl-)amino piperidine-1-yl]-3-fluorophenyl]-2oxo-oxazolidin-5-yl]methyl]acetamide and 5- nitro thiophen-2-carboxaldehyde following Method B.

15 δ ppm (CDCl₃) : 7.79 (d, 1H), 7.41 (dd, 1H), 7.05 (d, 1H) 6.93 (t, 1H), 6.85 (d, 1H), 6.11 (bs, 1H), 4.01 (t, 1H) 3.82-3.45 (m, 7H), 2.66 (m, 3H), 2.37 (s, 3H), 2.02 (s, 3H) 1.82-1.25 (m, 4H)

Compound No. 52: (S)-N-[[3-[4-[4-(N-methyl-N-2-thienylmethyl)aminopiperidine-1-yl]-3-fluorophenyl]-2oxo-oxazolidin-5-yl]methyl]acetamide

20 The title compound was made using (S)-N-[[3-[4-[4-(N-methyl-)amino piperidine-1-yl]-3-fluorophenyl]-2oxo-oxazolidin-5-yl]methyl]acetamide and thio-phen-2-carboxaldehyde following Method B.

Compound No. 53: (S)-N-[[3-[4-[4-(N-methyl-N-(5-methyl-2-thienyl-methyl)aminopiperidine-1-yl]-3-fluorophenyl]-2oxo-oxazolidin-5-yl] methyl]-acetamide

The title compound was made using (S)-N-[[3-[4-[4-(N-methyl-)amino piperidine-1-yl]-3-fluorophenyl]-2oxo-oxazolidin-5-yl]methyl]acetamide and 5-methyl-thiophen-2- carboxaldehyde following Method B.

Compound No. 54: (S)-N-{3-[4-[4-(N-methyl,2-(5-bromo)thienylmethyl)amino-piperidine-1-yl]-3-fluorophenyl]-2oxo-oxazolidin-5-yl methyl]acetamide.

The title compound was made using (S)-N-[[3-[4-[4-(N-methyl-)amino piperidine-1-yl]-3-fluorophenyl]-2oxo-oxazolidin-5-yl]methyl]acetamide and 5-bromo,-thiophen-2- carboxaldehyde Method B.

Analogues of of (S)-N-[[3-[3[Fluoro-4-(N-1-homopiperaziny]phenyl]-2-oxo-5-oxazolidinyl] methyl] acetamide (Core V)

The heteroaromatic group with the corresponding appendage can be introduced on the nitrogen atom of ring C of compounds of Formula I by one of the methods described below:

Method-A:

General procedure was same as described earlier in section 7.1.1.1 (Method A) described earlier for example Rbx-6408. Only the core amine of Formula V is (S)-N-{3-[4-[4-N-methylaminopeperidin-1-yl]-3-fluorophenyl]-2-oxo-oxazolidin-5-yl]-methyl acetamide (core V).

Compound No. 55: (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-furyl(5-formyl)methyl}]-homopiperazinyl]phenyl]2-oxo-5-oxazolidinyl)methyl]acetamide

Preparation of (S)-N-[[3-[3-Fluoro-4-(N-1-homopiperazinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide

5 **(a) Preparation of 1-(2-Fluoro-4-nitrophenyl)homopiperazine.**

To homopiperazine (5g, 0.05 mol) in acetonitrile (30 mL), 3,4-difluoronitrobenzene (3.17 g, 0.02 mol) was added and the reaction mixture was heated to reflux for 4 hrs. Then the solvent was evaporated and the residue taken in EtOAc and washed with water and brine solution. The EtOAc layer was dried over
10 anhyd Na₂SO₄ and evaporated in *vacuo*. The residue was digested with ether-hexane (1:20), decanted and dried in *vacuo* to get 3.7g of final product.

δppm (CDCl₃): 7.9 (m, 2H, Ar-H), 6.75 (t, 1H, Ar-H) 3.64 (m, 4H, CH₂), 3.08 (m, 2H, CH₂), 2.91 (m, 2H, CH₂), 1.96 (m, 2H, CH₂).

15 **(b) Preparation of 1-(2-Fluoro-4-nitrophenyl)-4-tert-butoxycarbonyl-homopiperazine.**

To 1-(2-Fluoro-4-nitrophenyl)homopiperazine (3.5 g, 14.6 mmol) in dichloromethane (100 mL) cooled to 5°C, triethylamine (0.2 mL, 1.46 mmole) and *tert*-butoxydicarbonate (4.15 g, 19.03 mmol) was added and the reaction mixture was stirred for 18 hrs. The solvent was evaporated and to the residue hexane was added.
20 The product precipitating out was filtered, washed with hexane and dried in air to yield 4.0g of the final product.

δppm (CDCl₃): 7.93 (m, 2H, Ar-H), 6.78 (t, 1H, Ar-H), 3.63 (m, 6H, CH₂), 3.43 (m, 2H, CH₂), 1.97 (m, 2H, CH₂), 1.50 (s, 9H, t-Bu).

(c) **3-Fluoro-4-(N-*tert*-butoxycarbonylhomopiperazinyl)aniline.**

To 1-(2-Fluoro-4-nitrophenyl)-4-*tert*-butoxycarbonylhomopiperazine (3.2g, 9.4 mmole) in methanol (30 mL), 10% palladium/carbon was added and shaken in a Parr hydrogenation apparatus under 40 psi of hydrogen gas for 3 hrs. Then the reaction mixture was filtered over celite and the filtrate evaporated in vacuum to yield 2.64 g of the final product.

δ ppm (CDCl₃) : 6.81 (t, 1H, Ar-H), 6.38 (m, 2H, Ar-H) 3.53 (m, 4H, CH₂) 3.21 (m, 4H, CH₂), 2.86 (br s, NH₂), 1.95 (m, 2H, CH₂), 1.45 (s, 9H, t-Bu).

(d) **N-Benzylloxycarbonyl-3-fluoro-4-(N-*tert*-butoxycarbonylhomopiperazinyl) aniline.**

To 3-Fluoro-4-(N-*tert*-butoxycarbonylhomopiperazinyl)aniline (2.6g, 8.4 mmol) in THF (25 ml) cooled to 5°C, sodium bicarbonate (0.85 g 10.1 mmol), was added and then benzylchloroformate (1.72g, 10 mmol) was added dropwise. The reaction mixture was stirred for 18 hrs. at R.T. and then filtered. The filtrate was evaporated in *vacuo*. The residue was dissolved in dichloromethane and washed with saturated sodium bicarbonate solution and brine water. The organic layer was dried over anhyd Na₂SO₄ and evaporated in *vacuo* to give 5.04 g of final product.

δ ppm (CDCl₃) : 7.35 (s, 6H, Ar-H), 6.84 (m, 2H, Ar-H), 6.54 (s, 1H, NH), 5.17 (s, 2H, CH₂), 3.2-3.61 (m, 8H, CH₂), 1.93 (m, 2H, CH₂), 1.45 (s, 9H, t-Bu).

(e) **(R)- [N-3-[3-Fluoro-4-[N-1-(4-*tert*-butoxycarbonyl)homopiperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methanol**

To N-benzylloxycarbonyl-3-fluoro-4-(N-*tert*-butoxycarbonylhomopiperazinyl)aniline (2.5 g, 5.6 mmol) dissolved in dry THF(25 mL), cooled to -78°C, butyl

lithium(4.8 mL, 15% sol. in hexane, 11.3 mmol) was added under +ve pressure of nitrogen. The reaction mixture was stirred at -78°C for 1.5 hrs. Then R-glycidyl butyrate (0.89 g, 6.2 mmol) was added and the reaction mixture was stirred at -78°C for 1hr and then at R.T. for 18 hrs. To it 25 mL of satd ammonium chloride solution was added and the reaction mixture extracted with EtOAc. The combined organic layers were washed with water and brine water, dried over anhydrous Na₂SO₄ and evaporated in *vacuo*. The crude product (~3g) was purified by column chromatography (3% MeOH/CHCl₃) to yield 0.41 g of final product.

δppm (CDCl₃) : 7.38 (d, 1H, ArH), 7.04 (d, 1H, Ar-H), 6.87 (t, 1H, Ar-H), 4.72 (m, 1H, CH), 4.1-3.2 (m, 11H, CH₂), 2.18 (br s, 1H), 1.94 (m, 2H, CH₂), 1.45 (s, 9H, t-Bu).

(f) (R)-[N-3[3-Fluoro-4-[N-1-(4-*tert*-butoxycarbonyl)homopiperazinyl]phenyl]-2-oxo-5-oxazolidinyl] methyl methanesulfonate.

To the (R)-[N-3[3-Fluoro-4-[N-1-(4-*tert*-butoxycarbonyl)homopiperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methanol (1.55 g, 3.8 mmol) in dichloromethane (10 mL) cooled to 5°C, triethylamine (0.76 g, 7.6 mmol) and methanesulfonylchloride (0.6 g, 5.3 mmoles) were added and the reaction mixture was stirred for 1 hr. Then the reaction mixture was diluted with dichloromethane and washed with saturated sodium bicarbonate solution and brine. The organic layer was dried over anhydrous sodium sulfate and evaporated in *vacuo* to yield 1.39 of product.

δppm (CDCl₃) : 7.32 (d, 1H, ArH), 7.02 (d, 1H, Ar-H), 6.87 (t, 1H, Ar-H), 4.89 (m, 1H, CH), 4.47 (m, 2H, CH₂), 4.09 (t, 1H, CH), 3.89 (m, 1H, CH), 3.65-3.2 (m, 8H, CH₂), 3.1 (s, 3H, CH₃), 1.94 (m, 2H, CH₂), 1.45 (s, 9H, t-Bu).

(g) (R)-[N-3[3-Fluoro-4-[N-1-(4-*tert*-butoxycarbonyl)homopiperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methylazide.

To (R)-[N-3[3-Fluoro-4-[N-1-(4-*tert*-butoxycarbonyl)homopiperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl methanesulfonate compound (1.21 g, 2.5
5 mmoles) in DMF(10 mL), sodium azide (0.81g, 12 mmoles) was added and the reaction mixture heated to 80°C for 5 hrs. The solid was filtered off and the filtrate evaporated in *vacuo*. The residue was dissolved in chloroform and washed with water and brine solution. The organic layer was dried over anhyd. Na₂SO₄ and evaporated in *vacuo* to yield 1.2 g of the product.

10 δ ppm (CDCl₃): 7.32 (d, 1H, Ar-H), 7.04 (d, 1H, Ar-H), 6.87 (t, 1H, Ar-H), 4.75 (m, 1H, CH), 4.02 (t, 1H, CH), 3.8-3.2(m, 1H, CH₂), 1.92 (M, 2H, CH₂), 1.45 (s, 9H, t-Bu).

(h) (R)-[N-3-[3-Fluoro-4-[N-1-(4-*tert*-butoxycarbonyl)homopiperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methylamine.

15 To (R)-[N-3[3-Fluoro-4-[N-1-(4-*tert*-butoxycarbonyl)homopiperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methylazide (1.1 g, 2.5 mmol) in methanol (10 mL), 10% palladium/carbon (0.22 g) was added and the reaction mixture shaken in a Parr hydrogenation apparatus under 40 psi hydrogen pressure for 5 hrs. The reaction was filtered over celite and the filtrate evaporated in *vacuo* to yield 0.9g of product. The
20 product was used as such in next step without further purification and characterization.

(i) (S)-N-[[3-[3-Fluoro-4-[N-1-(4-tert-butoxycarbonyl)homopiperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide.

To (R)-[N-3-[3-Fluoro-4-[N-1-(4-tert-butoxycarbonyl)homopiperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methylamine (0.77 g, 1.9 mmol) in dichloromethane (10 mL), triethylamine (0.21 g, 2.17 mmol) and acetic anhydride (0.21 g, 2 mmol) were added and the reaction mixture was stirred at R.T. for 30 minutes. Then the reaction mixture was diluted with dichloromethane and washed with saturated sodium bicarbonate solution and brine water. The organic layer was dried over anhydrous sodium sulfate and evaporated in vacuo. The residue was purified by column chromatography (2% MeOH/CHCl₃) to yield 0.48g of final product.

δ ppm (CDCl₃): 7.35(d, 1H, Ar-H), 7.02(d,1H, Ar-H), 6.86(t, 1H, Ar-H), 5.96(t, 1H, NH), 4.73(m, 1H, CH), 3.99(t, 1H, CH), 3.25-3.8(m, 1H, CH₂), 2.01(s, 3H, CH₃), 1.95(m, 2H, CH₂), 1.44(s, 9H, t-Bu).

(j) (S)-N-[[3-[3[Fluoro-4-(N-1-homopiperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

To (S)-N-[[3-[3-Fluoro-4-[N-1-(4-tert-butoxycarbonyl)homopiperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide (0.5g, 1.11 mmol) in dichloromethane (8 mL), trifluoroacetic acid (2 mL) was added and stirred for 2 hrs. Then the reaction mixture was evaporated and dried in vacuo. To the residue in acetone (10 mL), potassium carbonate (0.78 g, 5.55 mmol) was added and stirred for 15 mts. Then the reaction mixture was filtered and the filtrate evaporated in vacuo to yield the product in quantitative yield. This product was used as such in next step without further characterization.

Compound No. 55: (S)-N[[3-[3-Fluoro-4-[N-1[4-(2-furyl(5-formyl)methyl]]homopiperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

The title compound was made with (S)-N-[[3-[3[Fluoro-4-(N-1-homopiperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide and 2-formyl-5-chloromethylfuran using Method A.

δ ppm (CDCl₃) : 9.61(s, 1H, CHO), 7.35(d, 1H, Ar-H), 7.2(d, 1H, Ar-H), 7.02(d, 1H, Ar-H), 6.83(t, 1H, Ar-H), 6.48(s, 1H, Ar-H), 5.96(t, 1H, NH), 4.72(m, 1H, CH), 4.71(t, 1H, Ar-H), 4.14 (s, 1H, CH₂), 3.2-3.8(m., 7H, CH₂), 2.8-3(m, 4H, CH₂), 2.09(m, 5H, CH₂, CH₃)

Compound No. 56: (S)-N[[3-[3-Fluoro-4-[N-1[4-(2-thienylacetyl)]homopiperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

The title compound was made with (S)-N-[[3-[3[Fluoro-4-(N-1-homopiperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide and 2-thiophenacetylchloride using Method A.

δ ppm (CDCl₃) : 7.34(m, 1H, Ar-H), 7.18(t, 1H, Ar-H), 7.2-6.78(m, 4H, Ar-H), 6.22(t, 1H, NH), 4.74(m, 1H, CH), 4.2-3.52(m, 10H, CH₂), 3.52-3.15(m, 4H, CH₂), 2.01(m, 5H, CH₂, CH₃)

Compound No. 57: (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-thienyl(5-nitro)methyl}]homopiperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

The title compound was made with (S)-N-[[3-[3[Fluoro-4-(N-1-homopiperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl acetamide and 5-nitro -2-thiophencarboxaldehyde using Method B.

δ ppm (CDCl₃) : 7.78(s, 1H, Ar-H), 7.35(d, 1H, Ar-H), 7.04(m, 1H, Ar-H), 6.87(m, 2H, Ar-H), 5.99(t, 1H, Ar-H), 4.75(m, 1H, CH), 4.0(t, 1H, CH), 3.85(s, 2H, CH₂), 3.52-3.8(m, 3H, CH₂), 3.42(m, 4H, CH₂), 2.9-2.75(m, 4H, CH₂), 2.01(m, 5H, CH₂, CH₃)

Compound No. 58: (S)-N[[3-[3-Fluoro-4-[N-1[4-(3-furylmethyl)]homopiperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

The title compound was made with (S)-N-[[3-[3[Fluoro-4-(N-1-homopiperazinyl)phenyl]-2-oxo -5-oxazolidinyl]methyl]acetamide and 3-furaldehyde using Method B.

δ ppm (MeOD) : 7.71 (s, 1H, Ar-H), 7.59(s, 1H, Ar-H), 7.45(d, 1H, Ar-H), 7.12(d, 1H, Ar-H), 7.01(t, 1H, Ar-H), 6.6(s, 1H, Ar-H), 4.53(m, 8H, CH₂), 4.1(m, 2H, CH₂), 3.77(t, 1H, CH), 3.75-3.45(m, 5H, CH₂), 2.19(m, 2H, CH₂), 1.96(s, 3H, CH₃)

SCHEME-II

Compound No. 59: Preparation of (S)-N-[[3-[3-fluoro-4-[N-1{2-furyl-[4-(5-difluoromethyl) methyl]]piperazinyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide.

To a solution of (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-formyl)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide (80 mg, 0.18 mmol) in dichloromethane (4.0 ml) was added diethylamino sulfurtrifluoride (58 mg, 0.35 mmol). The whole reaction mixture was stirred at r.t. for 12 hr. TLC of the reaction mixture showed a faster moving spot. It was poured into a container and extracted with dichloromethane. Dichloromethane layer was washed with water, dried over anhydrous sodium sulphate. Solvent was removed. A gummy compound (60 m) was obtained.

δ ppm (CDCl₃) :7.44 (d, 1H), 7.05 (d, 1H), 6.92 (t, 1H) 6.62 (m, 2H), 6.36 (m, 1H), 6.12 (bs, 1H), 4.60 (bs, 1H), 3.24-2.95(m,6H), 2.74), 2.74 (bs, 4H) 4.01 (m, 1H) 3.68 (m, 3H), 2.00 (s, 3H).

Compound No. 74: Preparation of (S)-N-[[3-[3-fluoro-4-[N-1{2-furyl-[4-(5-fluoromethyl) methyl]]piperazinyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide.

The title compound was made from (S)-N-[[3-[3-Fluoro-4-[N-1{2-furyl-[4-(5-hydroxymethyl)methyl]]piperazinyl]-2-oxo-5-oxazolidinyl]methyl]acetamide by using the procedure mentioned.

Compound No. 60: (S)-N-[[3-[3-Fluoro-4-[N-1-[4-(2-furyl-(5-aldoxime)methyl]] piperazinyl] phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide.

To a solution of 5-formyl furyl derivative (140 mg 0.31 mmol) in dry pyridine was added hydroxylamine hydrochloride (26 mg, 0.38 mmol). The whole reaction mixture was stirred at 25°C for 4.0 hr. TLC of the reaction mixture was monitored. A slower moving spot was observed compare to starting compound. Pyridine was removed under reduced pressure and traces of pyridine were removed with toluene to yield title compound of 140 mg.

δ ppm ^1H NMR (DMSO- d_6): 8.70(d,2H),8.08-8.03(m,1H),7.65-7.61 (m,1H), 7.78 (d,1H), 7.24 7.11 (m,2H), 4.70 (d,1H) 4.49 (s,2H), 4.07 (t,1H), 1.82 (s,3H), 3.72 (m, 2H), 3.53-2.88 (m, 9H).

Compound No. 61: (S)-N-[[3-[3-Fluoro-4-[N-1[4-{2-furyl(5-aldoxime(methyl-4-(N-carboxyaminophenylacetate) methyl)}}piperazinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide

The title compound was prepared by using the procedure.

Compound No. 62: (S)-N-[[3-[3-Fluoro-4[N-1-[4-{2-furyl-(5-hydrazone)-methyl}]-piperazinyl]-phenyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide

To a solution of 5-formyl furyl derivative (140 mg, 0.31 mmol) in ethanol (4.0 ml) was added hydrazine hydrate (100mg) and catalytic amount of conc. sulfuric acid. The whole reaction mixture was stirred at 25°C for 48 hr. TLC of the reaction mixture showed no changes. Stirring was continued for another 12 hr. no change in TLC was observed.

Solvent was evaporated to dryness and the solid residue was digested with ether to give 100 mg of title compound of m.p. 78-181°C.

5 δ ppm (CDCl₃): δ =7.61 (s,1H), 7.42 (dd,1H), 7.04 (t,1H), 6.92 (t,1H), 6.44 (d,1H), 6.28 (bs,2H), 5.60 (bs,2H), 4.77 (bs,1H), 4.02 (t,1H), 3.77-3.61 (m,8H), 3.10 (bs,1H), 2.71 (bs,1H), 2.02 (s,3H).

Compound No. 63: Preparation of (S)-N-[[3-[3-Fluoro-4-[N-1{2-furyl-[4-(5-hydroxymethyl)methyl]] piperazinyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

To a solution 5-formyl-2-derivative (100 mg, 0.22 mmol) in ethanol was added Sodium borohydride (solid, 17 mg, 0.44 mmol). The whole reaction mixture was stirred at 25°C for 60 hr. TLC of the reaction mixture in chloroform : Methanol (9:1) showed a slower moving spot. The solvent was removed under reduced pressure. The residue was dissolved in chloroform and washed with water, dried over anhydrous sodium sulphate and solvent was removed to give title compound in 70 mg as gum.

15 δ ppm (CDCl₃) : 7.45 (d,1H), 7.06 (d,1H), 6.94 (d, 1H), 6.23 (dd,1H), 6.00 (bs,1H), 4.70 (bs, 1H), 4.03 (t, 1H), 3.12 (bs, 4H), 2.69 (bs, 4H), 4.62 (s, 2H), 3.76-3.4 (m, 6H), 2.03 (s, 3H).

Compound No. 64: (S)-N-[[3-[3-Fluoro-4-[N-1[4-{2-furyl(5-cyano)methyl]] piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

20 (S)-N-[[3-[3-Fluoro-4-[N-1[4-{2-furyl(5-aldoxime)methyl]] piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide (6126, 3.5g,0.76 mmol) was taken in CH₂Cl₂ (5 mL) and triethyl amine(1.5g, 1.5 mmol) was added and the r.m. was

maintained at -78°C. Triflic anhydride (4.3g, 1.5 mmol) in CH₂Cl₂ (2 mL) was added dropwise after complete addition, the temperature of the reaction mixture was allowed to rise to r.t. in 2 hrs. The r.m. is concentrated under vacuum. H₂O (10 mL) was added and extracted with CH₂Cl₂ (3x10 mL). The combined organic layer was dried
 5 over Na₂SO₄, filtered and concentrated to obtain the title compound.

NMR(CDCl₃); 7.44-6.10(m, 6H), 4.74(m,1H), 4.00(t, 2H), 3.73-3.62(m,5H), 3.09-2.68 (m, 8H,), 2.01(s,3H)

Compound No. 65: (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-carboxy)methyl}]-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide

10 The title compound was made using (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-formyl)methyl}]]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide in a solution of freshly prepared Ag₂O and stirring for 30 min. The r.m. was filtered, acidified to pH 5 and extracted with EtOAc, dried over Na₂SO₄, filtered and concentrated.

15 δppm (CDCl₃+ MeOD) 8.01-7.03 (m, 5H), 4.81 (m, 1H), 4.07 (t, 1H), 3.8-3.3v (m, 5H), 3.0(s,4H), 2.7 (s, 4H) 2.01(s,3H).

Compound No. 66: (S)-N-[[3-Fluoro-4-[N-1[5-(1,3-dioxane)-2-furylmethyl]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide

20 The title compound was made using (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-formyl)methyl}]]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide with 1,3-propane diol and BF₃ etherate using standard literature procedures.

Compound No. 67: (S)-N-[[3-Fluoro-4-[N-1[5-(formamido)-2-furylmethyl]-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide

The title compound was made reacting (S)-N-[[3-Fluoro-4-[N-1[4-(2-furyl-(5-carboxyethyl)methyl)piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide
5 with aqueous ammonia solution followed by wet extraction with ethyl acetate.

δ ppm (CDCl₃+ DMSO-d₆) 7.46-6.37 (m, 6H), 4.7 (m, 1H), 4.0-3.4 (m, 5H), 2.9 (s, 4H), 2.4 (s, 4H), 2.01 (s, 3H).

Compound No. 68: (S)-N-[[3-Fluoro-4-[N-1[5-(morpholine-1-carbonyl)-2-furylmethyl]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide

10 The title compound was made by reacting (S)-N-[[3-Fluoro-4-[N-1[4-(2-furyl-(5-carboxyethyl)methyl)piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide with morpholine using standard literature procedure.


Compound No. 69: (S)-N-[[3-Fluoro-4-[N-1[5-(4-(tert butoxy carbonyl)amino piperidine)-2-furylmethyl]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide
15

The title compound was made by reacting (S)-N-[[3-Fluoro-4-[N-1[4-(2-furyl-(5-carboxy)methyl)piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide with thionyl chloride and 4-(tert butoxy carbonyl)amino piperidine.

20 While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.

CLAIMS:

1. A compound having the structure of Formula I

**FORMULA I**

and its pharmaceutically acceptable salts, enantiomers, diastereomers, N-oxides, prodrugs or metabolites, wherein

T is five to seven membered heterocyclic ring, aryl, substituted aryl, bound to the ring **C** with a linker **w** and the heterocyclic and aryl rings are further substituted by a group represented by **R**,

wherein **R** is selected from the group consisting of $-\text{CN}$, COR_5 , COOR_5 , $\text{N}(\text{R}_6, \text{R}_7)$, $\text{CON}(\text{R}_6, \text{R}_7)$, CH_2NO_2 , NO_2 , CH_2R_8 , CHR_9 , $-\text{CH}=\text{N}-\text{OR}_{10}$, $-\text{C}=\text{CH}-\text{R}_5$, wherein R_5 is selected from the group consisting of H, optionally substituted $\text{C}_1\text{-C}_{12}$, alkyl, $\text{C}_3\text{-}_{12}$, cycloalkyl, aryl, heteroaryl; R_6 and R_7 are independently selected from the group consisting of H, optionally substituted $\text{C}_1\text{-}_{12}$ alkyl, $\text{C}_3\text{-}_{12}$ cycloalkyl, $\text{C}_1\text{-}_6$ alkoxy; R_8 and R_9 are independently selected from the group consisting of H, $\text{C}_1\text{-}_6$ alkyl, F, Cl, Br, $\text{C}_1\text{-}_{12}$ alkyl substituted with one or more of F, Cl, Br, I, OR_4 , SR_4 , $\text{N}(\text{R}_6, \text{R}_7)$ wherein R_4 is selected from the group consisting of H, $\text{C}_1\text{-}_{12}$ alkyl, $\text{C}_3\text{-}_{12}$ cycloalkyl, $\text{C}_1\text{-}_6$ alkoxy, $\text{C}_1\text{-}_6$ alkyl substituted with one or more F, Cl, Br, I or OH and R_6 and

R_7 are the same as defined earlier, R_{10} is selected from the group consisting of H, optionally substituted from H, optionally substituted C_{1-12} alkyl, C_{3-512} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkyl, aryl, heteroaryl;

n is an integer in the range from 0 to 3;

X is CH, CH-S, CH-O and N


Y and Z are independently selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{3-12} cycloalkyl, C_{0-3} bridging group;

U and V are independently selected from the group consisting of optionally substituted C_{1-6} alkyl, F, Cl, Br, C_{1-12} alkyl substituted with one or more of F, Cl, Br, I, preferably U and V are hydrogen or fluoro;

W is selected from the group consisting of CH_2 , CO, CH_2NH , $-NHCH_2$, $-CH_2NHCH_2$, $-CH_2-N(R_{11})CH_2-$, $CH_2(R_{11})N-$, $CH(R_{11})$, S, $CH_2(CO)$, NH wherein R_{11} is optionally substituted with C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkyl, aryl, heteroaryl,

R_1 is selected from the group consisting of $-NHC(=O)R_2$ wherein R_2 is hydrogen, C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkyl substituted with one or more of F, Cl, Br, I or OH; $N(R_3, R_4)$; $-NR_2C(=S)R_3$; $-NR_2C(=S)SR_3$ wherein R_2 is the same as defined above and R_3 and R_4 are independently selected from the group consisting of H, C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkyl substituted with one or more of F, Cl, Br, I or OH.

2. A compound having structure of Formula II



FORMULA II

and its pharmaceutically acceptable salts, enantiomers, diastereomers, N-oxides, prodrugs or metabolites wherein

X is CH, CH-S, CH-O and N;

Y and Z are independently selected from the group consisting of hydrogen, C₁₋₆ alkyl, C₃₋₁₂ cycloalkyl, C₀₋₃ bridging group;


U and V are independently selected from the group consisting of optionally substituted C₁₋₆ alkyl, F, Cl, Br, C₁₋₁₂ alkyl substituted with one or more of F, Cl, Br, I, preferably **U and V** are hydrogen or fluoro;

W is selected from the group consisting of CH₂, CO, CH₂NH, -NHCH₂, -CH₂NHCH₂, -CH₂-N(R₁₁)CH₂-, CH₂(R₁₁)N-, CH(R₁₁), S, CH₂(CO), NH wherein R₁₁ is optionally substituted with C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkyl, aryl, heteroaryl;


n is an integer in the range from 0 to 3; and,

Q and P are independently selected from the group consisting of -CN, COR₅, COOR₅, N(R₆, R₇), CON(R₆, R₇), CH₂NO₂, NO₂, CH₂R₈, CHR₉, -CH=N-


OR₁₀, C=CH-R₅, wherein R₅ is selected from the group consisting of H, optionally substituted C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, aryl, heteroaryl; R₆ and R₇ are independently selected from the group consisting of H, optionally substituted C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, C₁₋₆ alkoxy; R₈ and R₉ are independently selected from the group consisting of H, C₁₋₆ alkyl, F, Cl, Br, C₁₋₁₂ alkyl substituted with one or more of F, Cl, Br, I, OR₄, SR₄, wherein R₄ is selected from the group consisting of H, C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkyl substituted with one or more F, Cl, Br, I or OH, N(R₆, R₇), R₁₀ is selected from the group consisting of H, optionally substituted C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkyl, aryl, heteroaryl except W= (CO), Q and P =H, ring C in Formula II is 6-8 membered or of larger size and the larger rings have either two or three carbons between each nitrogen atom, comprising of




and may be bridged to form a bicyclic system as shown below,




ring C is optionally substituted by Y and Z with alkyl groups, cycloalkyl groups, fluoro group, carboxylic and corresponding esters, amides, substituted alkyls or bridging alkyl groups are as shown below:



six membered ring C with $X = -CH-(NHR_{11})$, (wherein R_{11} is the same as defined earlier) is selected from the group consisting of the following rings;



wherein M = Sulphur is shown by compounds Formula III,



Formula III

wherein P, Q, U, V, X, Y, Z, W and n in Formula III are the same as previously defined.

3. A compound selected from the group consisting of
 1. (S)-N-[[3-[3-Fluoro-4-[N-1-[4-(2-furoyl) piperazinyl]]phenyl]-2-oxo-5-oxazolidinyl] methyl]acetamide
 2. (S)-N-[[3-[3-Fluoro-4-[N-1[4-{2-furyl(5-formyl)methyl}] piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
 3. (S)-N-[[3-[3-Fluoro-4-[N-1[4-(2-furyl-(5-carboxyethyl)methyl)piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
 4. (S)-N-[[3-[3-Fluoro-4-[N-1[4-(5-bromo-2-furoyl)]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl] methyl]acetamide
 5. (S)-N-[[3-[3-Fluoro-4-[N-1[4-(5-chloromethyl-2-furoyl)piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
 6. (S)-N-[[3-[3-Fluoro-4-[N-1[4-(5-nitro-2-furoyl)piperazinyl]phenyl]-2-oxo-5-oxazolidinyl] methyl]acetamide
 7. (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-(2-thienyl)dicarbonyl}] piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide
 8. (S)-N[[3-[3-Fluoro-4-[N-1[4-(3-furoyl)]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl] acetamide

9. (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-furyl(5-bromo)methyl}]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide
10. (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-thienyl(5-chloro)methyl}]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide
11. (S)-N[[3-[3-Fluoro-4-[N-1[4-(2-furylmethyl)]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide
12. (S)-N[[3-[3-Fluoro-4-[N-1[4-(2-thienylmethyl)]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide
13. (S)-N[[3-[3-Fluoro-4-[N-1[4-(2-thienylacetyl)]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide
14. (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-thienyl(4-bromo)methyl}]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide
15. (S)-N[[3-[3-fluoro-4-[N-1[4-{2-furyl(5-nitro)methyl}]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide.
16. Hydrochloric salt of (S)-N[[3-Fluoro-4-[N-1[4-{2-furyl(5-nitro)methyl}]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide
17. Citrate salt of (S)-N[[3-Fluoro-4-[N-1[4-{2-furyl(5-nitro)methyl}]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide
18. (S)-N[[3-[3-Fluoro-4-[N-1[4-(2-pyrrolylmethyl)]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide
19. (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-thienyl(3-methyl)methyl}]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide
20. (S)-N[[3-[3-Fluoro-4-[N-1[4-(3-furylmethyl)]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide
21. (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-thienyl(5-methyl)methyl}]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide
22. (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-pyrrole(1-methyl)methyl}]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide
23. (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-thienyl(5-nitro)methyl}]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide
24. (S)-N[[3-[3-Fluoro-4-[N-1[4-[2-furyl{5-(N-thiomorpholinyl)methyl}]methyl]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide


25. (S)-N-[[3-[3-Fluoro-4-[N-1[4-[2-furyl{5-(N-morpholinyl)methyl}methyl]]piperazinyl] phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide
26. (S)-N-[[3-[3-Fluoro-4-[N-1[4-{2-furyl(5-acetoxymethyl)methyl}]piperazinyl] phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
27. (S)-N-[[3-[3-Fluoro-4-[N-1[4-{2-thienyl(5-bromo)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
28. (S)-N-[[3-[3-Fluoro-4-[N-1[4-(5-nitro-2-furylmethyl)piperazinyl] phenyl]- 2-oxo-oxazolidinyl]methyl]dichloroacetamide
29. (S)-N-[[3-[3-Fluoro-4-[N-1[4-(5-nitro-2-thienoyl)]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide hydrochloride
30. (S)-N-[[3-[3-Fluoro-4-[N-1[4-(2',2'- diphenyl-2' hydroxy acetyl)]piperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide
31. (S)-N-[[3-[3-Fluoro[4-[3-(1 α ,5 α ,6 α)-6-[N-(5-nitro-2-furoyl)-N-methyl]amino]-3-azabicyclo-[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
32. (S)-N-[[3-[3-Fluoro[4-[3-(1 α ,5 α ,6 α)-6-[N-(3-furoyl)-N-methyl]amino]-3-azabicyclo-[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
33. (S)-N-[[3-[3-Fluoro[4-[3-(1 α ,5 α ,6 α)-6-[N-(5-bromo -2-furoyl)-N-methyl]amino]-3-azabicyclo-[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
34. (S)-N-[[3-[3-Fluoro[4-[3-(1 α ,5 α ,6 α)-6-[N-(5-nitro-2-thienylmethyl)-N-methyl]amino]-3-azabicyclo-[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
35. (S)-N-[[3-[3-Fluoro[4-[3-(1 α ,5 α ,6 α)-6-[N-(5-nitro-2-furylmethyl)-N-methyl]amino]-3-azabicyclo-[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
36. (S)-N-[[3-[3-Fluoro[4-[3-(1 α ,5 α ,6 α)-6-[N-(5-formyl-2-furylmethyl)-N-methyl]amino-methyl]-3-azabicyclo-[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
37. (S)-N-[[3-[3-Fluoro[4-[3-(1 α ,5 α ,6 α)-6-[N-(5-carboxyethyl-2-furylmethyl)-N-methyl] aminomethyl]-3-azabicyclo-[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide

38. (S)-N-[[3-[3-Fluoro[4-[3-(1 α ,5 α ,6 α)-6-[N-(2-thiopheneacetyl)-N-methyl]aminomethyl]-3-azabicyclo-[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
39. (S)-N-[[3-[3-Fluoro[4-[3-(1 α ,5 α ,6 α)-6-[N-(5-nitro-2-thienylmethyl)-N-methyl]amino-methyl]-3-azabicyclo-[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
40. (S)-N-[[3-[3-Fluoro[4-[3-(1 α ,5 α ,6 α)-6-[N-(5-nitro-2-furylmethyl)-N-methyl]amino-methyl]-3-azabicyclo-[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
41. (S)-N-[[3-[4-[4-(N-methyl-N-2-furyl(5-formyl)methylaminopiperidine-1-yl]-3-fluorophenyl]-2-oxo-oxazolidin-5-yl]methyl]acetamide
42. (S)-N-[[3-[4-[4-(N-methyl-N-(3,5-difluorobenzoyl)aminopiperidine-1-yl]-3-fluorophenyl]-2-oxo-oxazolidin-5-yl]methyl]acetamide.
43. (S)-N-[[3-[4-[4-(N-methyl-N-(5-bromo-2-furoyl)aminopiperidine-1-yl]-3-fluorophenyl]-2-oxo-oxazolidin-5-yl]methyl]acetamide
44. (S)-N-[[3-[4-[4-(N-methyl-N-(5-nitro-2-furoyl)aminopiperidine-1-yl]-3-fluorophenyl]-2-oxo-oxazolidin-5-yl]methyl]acetamide
45. (S)-N-[[3-[4-[4-(N-methyl-N-3-furoyl)aminopiperidine-1-yl]-3-fluorophenyl]-2-oxo-oxazolidin-5-yl]methyl]acetamide.
46. (S)-N-{3-[4-[4-(N-methyl, N-2-furoyl)aminopiperidine-1-yl]-3-fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl]acetamide
47. (S)-N-{3-[4-[4-(N-methyl,2-thiopheneacetyl)aminopiperidine-1-yl]-3-fluorophenyl]-2-oxo oxazolidin-5-ylmethyl]acetamide
48. (S)-N-[[3-[4-[4-(N-methyl-N-2-furylmethyl)aminopiperidine-1-yl]-3-fluorophenyl]-2-oxo-oxazolidin-5-yl]methyl]acetamide
49. (S)-N-[[3-[4-[4-(N-methyl-N-3-furyl)aminopiperidine-1-yl]-3-fluorophenyl]-2-oxo-oxazolidin-5-yl]methyl]acetamide.
50. (S)-N-[[3-[4-[4-(N-methyl-N-2-furyl(5-nitro)methyl)aminopiperidine-1-yl]-3-fluorophenyl]-2-oxo-oxazolidin-5-yl]methyl]acetamide.
51. (S)-N-[[3-[4-[4-(N-methyl-N-2-thienyl(5-nitro)methyl)aminopiperidine-1-yl]-3-fluorophenyl]-2-oxo-oxazolidin-5-yl]methyl]acetamide.

52. (S)-N-[[3-[4-[4-(N-methyl-N-2-thienylmethyl)aminopiperidine-1-yl]-3-fluorophenyl]-2-oxo-oxazolidin-5-yl]methyl]acetamide.
53. (S)-N-[[3-[4-[4-(N-methyl-N-(5-methyl-2-thienylmethyl)aminopiperidine-1-yl]-3-fluorophenyl]-2-oxo-oxazolidin-5-yl]methyl]acetamide
54. (S)-N-{3-[4-[4-(N-methyl,2-(5-bromo)thienylmethyl)aminopiperidine-1-yl]-3-fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl]acetamide
55. (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-furyl(5-formyl)methyl}]homopiperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide
56. (S)-N[[3-[3-Fluoro-4-[N-1[4-(2-thienylacetyl)]homopiperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide
57. (S)-N[[3-[3-Fluoro-4-[N-1[4-{2-thienyl(5-nitro)methyl}]homopiperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide
58. (S)-N[[3-[3-Fluoro-4-[N-1[4-(3-furylmethyl)]homopiperazinyl]phenyl]2-oxo-5-oxazolidinyl]methyl]acetamide
59. Preparation of (S)-N-[[3-[3-fluoro-4-[N-1{2-furyl-[4-(5-difluoromethyl)methyl}]piperazinyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide.
60. (S)-N-[[3-[3-Fluoro-4-[N-1[4-(2-furyl(5-aldoxime)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
61. (S)-N-[[3-[3-Fluoro-4-[N-1[4-{2-furyl(5-aldoxime(methyl-4-(N-carboxyaminophenyl acetate)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
62. (S)-N-[[3-[3-Fluoro-4[N-1-[4-{2-furyl(5-hydrazone)-methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide
63. Preparation of (S)-N-[[3-[3-Fluoro-4-[N-1{2-furyl-[4-(5-hydroxymethyl)methyl}]piperazinyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
64. (S)-N-[[3-[3-Fluoro-4-[N-1[4-{2-furyl(5-cyano)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
65. (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-carboxy)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
66. (S)-N-[[3-Fluoro-4-[N-1[5-(1,3-dioxane)-2-furylmethyl]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
67. (S)-N-[[3-Fluoro-4-[N-1[5-(formamido)-2-furylmethyl]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

68. (S)-N-[[3-Fluoro-4-[N-1[5-(morpholine-1-carbonyl)-2-furylmethyl]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide
 69. (S)-N-[[3-Fluoro-4-[N-1[5-(4-(tert butoxy carbonyl)amino piperidine)-2-furylmethyl]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide
 70. (S)-N-[[3-Fluoro-4-[N-1[4-{(Z)-2-methoxyimino-2-(2-furyl)acetyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
 71. (S)-N-[[3-[3-Fluoro[4-[3-(1 α ,5 α ,6 α)-6-[N-(2-thiopheneacetyl)-N-methyl]amino]-3-azabicyclo-[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
 72. (S)-N-[[3-[3-Fluoro[4-[3-(1 α ,5 α ,6 α)-6-[N-(5-formyl-2-furylmethyl)-N-methyl]amino]-3-azabicyclo-[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
 73. (S)-N-[[3-[3-Fluoro[4-[3-(1 α ,5 α ,6 α)-6-[N-(3-thienoyl)-N-methyl]amino]-3-azabicyclo[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
 74. (S)-N-[[3-[3-fluoro-4-[N-1{2-furyl-[4-(5-fluoromethyl)methyl}]piperazinyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide.
4. A pharmaceutical composition comprising the compound of claims 1, 2, or 3 and a pharmaceutical acceptable carrier.
 5. A pharmaceutical composition comprising a pharmaceutically effective amount of compound according to claims 1, 2, or 3, or a physiologically acceptable acid addition salt thereof with a pharmaceutical acceptable carrier for treating microbial infections.
 6. A method of treating or preventing microbial infections in a mammal comprising administering to the said mammal, the pharmaceutical composition according to claim 5.

7. A process for preparing a compound of Formula I



FORMULA I

and its pharmaceutically acceptable salts, enantiomers, diastereomers, N-oxides, prodrugs or metabolites, wherein

T is five to seven membered heterocyclic ring, aryl, substituted aryl, bound to the ring C with a linker w and the heterocyclic and aryl rings are further substituted by a group represented by R,

wherein R is selected from the group consisting of $-\text{CN}$, COR_5 , COOR_5 , $\text{N}(\text{R}_6, \text{R}_7)$, $\text{CON}(\text{R}_6, \text{R}_7)$, CH_2NO_2 , NO_2 , CH_2R_8 , CHR_9 , $-\text{CH}=\text{N}-\text{OR}_{10}$, $-\text{C}=\text{CH}-\text{R}_5$, wherein R_5 is selected from the group consisting of H, optionally substituted $\text{C}_1\text{-C}_{12}$, alkyl, $\text{C}_3\text{-}_{12}$, cycloalkyl, aryl, heteroaryl, R_6 and R_7 , are independently selected from the group consisting of H, optionally substituted $\text{C}_1\text{-}_{12}$ alkyl, $\text{C}_3\text{-}_{12}$ cycloalkyl, $\text{C}_1\text{-}_6$ alkoxy; R_8 and R_9 are independently selected from the group consisting of H, $\text{C}_1\text{-}_6$ alkyl, F, Cl, Br, $\text{C}_1\text{-}_{12}$ alkyl substituted with one or more of F, Cl, Br, I, OR_4 , SR_4 , $\text{N}(\text{R}_6, \text{R}_7)$ wherein R_4 is selected from the group consisting of H, $\text{C}_1\text{-}_{12}$ alkyl, $\text{C}_3\text{-}_{12}$ cycloalkyl, $\text{C}_1\text{-}_6$ alkoxy, $\text{C}_1\text{-}_6$ alkyl substituted with one or more F, Cl, Br, I or OH and R_6 and R_7 are the same as defined earlier, R_{10} is selected from the group consisting of

H, optionally substituted from H, optionally substituted C_{1-12} alkyl, C_{3-512} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkyl, aryl, heteroaryl;

n is an integer in the range from 0 to 3;

X is CH, CH-S, CH-O and N;


Y and Z are independently selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{3-12} cycloalkyl, C_{0-3} bridging group;

U and V are independently selected from the group consisting of optionally substituted C_{1-6} alkyl, F, Cl, Br, C_{1-12} alkyl substituted with one or more of F, Cl, Br, I, preferably U and V are hydrogen or fluoro;

W is selected from the group consisting of CH_2 , CO, CH_2NH , $-NHCH_2$, $-CH_2NHCH_2$, $-CH_2-N(R_{11})CH_2-$, $CH_2(R_{11})N-$, $CH(R_{11})$, S, $CH_2(CO)$, NH wherein R_{11} is optionally substituted with C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkyl, aryl, heteroaryl; and

R_1 is selected from the group consisting of $-NHC(=O)R_2$ wherein R_2 is hydrogen, C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkyl substituted with one or more of F, Cl, Br, I or OH; $N(R_3, R_4)$; $-NR_2C(=S)R_3$; $-NR_2C(=S)SR_3$ wherein R_2 is the same as defined above and R_3 and R_4 are independently selected from the group consisting of H, C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkyl substituted with one or more of F, Cl, Br, I or OH,

which comprises reacting an amine compound of Formula V




FORMULA V

with a heterocyclic compound of Formula R-T-W- R₁₂ wherein G in amines of Formula V is defined as NH, CH(NHR₁₃), -CH-CH₂NHR₁₃ wherein R₁₃ is H, ethyl, methyl, isopropyl, acetyl, cyclopropyl, alkoxy or acetyl and Y, Z, U, V, R₁, n, R, T and W are the same as defined earlier and R₁₂ is a suitable leaving group selected from the group comprising of fluoro, chloro, bromo, SCH₃, -SO₂CH₃, -SO₂CF₃ or OC₆H₅.

8. A process for preparing a compound of Formula I as claimed in claim 7, wherein W=CH₂ and R-T-W-R₁₂ is a five membered heterocyclic ring with aldehyde group and the compound of Formula I is produced by reductive amination.
9. A process for preparing a compound of Formula I as claimed in claim 7, wherein W = CO and R-T-W-R₁₂ is a five membered heterocyclic ring with carboxylic acid, and amino compound of Formula V is acylated with activated esters in presence of condensing agents comprising 1,3-dicyclohexylcarbodiimide (DCC) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC).

10. A process for the preparation of compound of Formula II



FORMULA II

wherein

n is an integer in the range from 0 to 3;

X is CH, CH-S, CH-O and N;

Y and Z are independently selected from the group consisting of hydrogen, C₁₋₆ alkyl, C₃₋₁₂ cycloalkyl, C₀₋₃ bridging group;


U and V are independently selected from the group consisting of optionally substituted C₁₋₆ alkyl, F, Cl, Br, C₁₋₁₂ alkyl substituted with one or more of F, Cl, Br, I, preferably U and V are hydrogen or fluoro;

W is selected from the group consisting of CH₂, CO, CH₂NH, -NHCH₂, -CH₂NHCH₂, -CH₂-N(R₁₁)CH₂-, CH₂(R₁₁)N-, CH(R₁₁), S, CH₂(CO), NH wherein R₁₁ is optionally substituted with C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkyl, aryl, heteroaryl; and


Q and P are independently selected from the group consisting of -CN, COR₅, COOR₅, N(R₆, R₇), CON(R₆, R₇), CH₂NO₂, NO₂, CH₂R₈, CHR₉, -CH=N-OR₁₀, C=CH-R₅, wherein R₅ is selected from the group consisting of H,

optionally substituted C_{1-12} alkyl, C_{3-12} cycloalkyl, aryl, heteroaryl; R_6 and R_7 are independently selected from the group consisting of H, optionally substituted C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy; R_8 and R_9 are independently selected from the group consisting of H, C_{1-6} alkyl, F, Cl, Br, C_{1-12} alkyl substituted with one or more of F, Cl, Br, I, OR_4 , SR_4 , wherein R_4 is the same as defined before, $N(R_6, R_7)$, R_{10} is selected from the group consisting of H, optionally substituted C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{1-6} alkoxy, C_{1-6} alkyl, aryl, heteroaryl except $W = (CO)$, Q and P = H.


Ring C in Formula II is 6-8 membered or of larger size and the larger rings have either two or three carbons between each nitrogen atom, comprising of




and may be bridged to form a bicyclic system as shown below,




ring C is optionally substituted by Y and Z with alkyl groups, cycloalkyl groups, fluoro group, carboxylic and corresponding esters, amides, substituted alkyls or bridging alkyl groups are as shown below:



six membered ring C with $X = -CH-(NHR_{11})$, (wherein R_{11} is the same as defined earlier) is selected from the group consisting of the following rings;




wherein M = Sulphur is shown by compounds of Formula III,




FORMULA III

wherein **P**, **Q**, **U**, **V**, **X**, **Y**, **Z**, **W** and **n** in Formula III are the same as previously defined, wherein the process comprising reacting a compound of Formula V



FORMULA V

with a compound of Formula VI




FORMULA VI

wherein **P**, **Q**, **R₁₂**, **Y**, **Z**, **G**, **n**, **U** and **V** are the same as defined earlier.

11. A process for preparing a compound of Formula II as claimed in claim 10, in a suitable solvent selected from the group consisting of dimethylformamide, dimethylacetamide, ethanol or ethylene glycol at a suitable temperature in the range of -70°C to 180°C in the presence of a suitable base selected from the group consisting of triethyl amine, diisopropyl amine, potassium carbonate and sodium bicarbonate.

12. A process of preparing a compound of Formula II as claimed in claim 10 wherein Formula VI is furalehyde and reductive alkylation of the amine of Formula V is performed with a reducing agent.
13. A process for preparing a compound of Formula II as claimed in claim 10 wherein Formula VI is furoic acid.
14. A process for preparing a compound of Formula II as claimed in claim 10 wherein the compounds of Formula II having carbonyl link are prepared by reacting heteroaromatic compound of the Formula VI including N- methyl pyrrole with the intermediate amine of Formula V in the presence of triphosgene or phosgene and carbonyl linkers are introduced between heteroaromatic compound comprising reacting 3- bromothiophene and amine of Formula V with carbon monoxide and the catalyst is selected from the group consisting of Pd (PPh₃)₂Cl₂ and extended chain pyrroles having dicarbonyl linkers are obtained by treatment of oxalyl chloride and amine of the Formula V.
15. A process for preparing a compound of Formula VIII



FORMULA VIII

wherein

n is an integer in the range from 0 to 3;

X is CH, CH-S, CH-O and N;


Y and Z are independently selected from the group consisting of hydrogen, C₁₋₆ alkyl, C₃₋₁₂ cycloalkyl, C₀₋₃ bridging group;

U and V are independently selected from the group consisting of optionally substituted C₁₋₆ alkyl, F, Cl, Br, C₁₋₁₂ alkyl substituted with one or more of F, Cl, Br, I, preferably U and V are hydrogen or fluoro;

W is selected from the group consisting of CH₂, CO, CH₂NH, -NHCH₂, -CH₂NHCH₂, -CH₂-N(R₁₁)CH₂-, CH₂(R₁₁)N-, CH(R₁₁), S, CH₂(CO), NH wherein R₁₁ is optionally substituted with C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkyl, aryl, heteroaryl;


Q and P are independently selected from the group consisting of -CN, COR₅, COOR₅, N(R₆, R₇), CON(R₆, R₇), CH₂NO₂, NO₂, CH₂R₈, CHR₉, -CH=N-OR₁₀, C=CH-R₅, wherein R₅ is selected from the group consisting of H, optionally substituted C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, aryl, heteroaryl; R₆ and R₇ are independently selected from the group consisting of H, optionally substituted C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, C₁₋₆ alkoxy; R₈ and R₉ are independently selected from the group consisting of H, C₁₋₆ alkyl, F, Cl, Br, C₁₋₁₂ alkyl substituted with one or more of F, Cl, Br, I, OR₄, SR₄, wherein R₄ is the same as defined before, N(R₆, R₇), R₁₀ is selected from the group consisting of H, optionally substituted C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkyl, aryl, heteroaryl except W= (CO), Q and P =H;

M = Sulphur is shown by compounds of Formula III



FORMULA III


and R_{15} is the same as Q defined earlier, comprising converting a compound of Formula VII



FORMULA VII


wherein in U, V, Y, Z, X, W, P, n and M are the same as defined earlier and R_{14} is any group which can be converted to group R_{15} in one to five steps.

16. A process for preparing a compound of Formula XI




FORMULA XI

($R_{16} = -CH_2F$ or $-CH_2F_2$) by reacting a compound of Formula IX



FORMULA IX


with sodium borohydride to produce a compound of Formula X



FORMULA X


and further reacting this compound with diethylamino sulfurtrifluoride to produce compound of Formula XI.

17. A process for preparing a compound of Formula XII



FORMULA XII


wherein $R_{17} = \text{---}=\text{N-OH}$ which comprises reacting (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-formyl)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]-methyl] acetamide of Formula IX



FORMULA IX

with hydroxylamine.


18. A process for preparing a compound of Formula XII



FORMULA XII

wherein $R_{17} = \text{CH}_2=\text{N}-\text{NH}_2$ which comprises reacting (S)-N-[[3-[3-Fluoro-4[N-1-[4-{2-furyl-(5-hydrazone)-methyl}]-piperazinyl]-phenyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide with hydrazine hydrate.


19. A process for preparing a compound of Formula XII



FORMULA XII

wherein $R_{17} = \text{CH}_2=\text{N}-\text{O}-\text{C}(=\text{O})-\text{NH}-\text{C}_6\text{H}_4-\text{CH}_2\text{COOCH}_3$ which comprises reacting (S)-N-[[3-[3-Fluoro-4-[N-1-[4-(2-furyl-(5-aldoxime)methyl] piperazinyl] phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide with isocyanate.


20. A process for preparing a compound of Formula XII



FORMULA XII

wherein $R_{17} = \text{CN}$ which comprises reacting (S)-N-[[3-[3-Fluoro-4-[N-1[4-{2-furyl(5-cyano)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide with triflic anhydride and triethylamine.


21. A process for preparing a compound of Formula XII



FORMULA XII

wherein $R_{17} = \text{---CH---}$ which comprises reacting (S)-N-[[3-Fluoro-4-[N-1[5-(1,3-dioxane)-2-furylmethyl]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide with 1,3-propane diol and BF_3 etherate.


22. A process for the preparation of the compound of Formula XIV



FORMULA XIV


wherein $R_{18} = \text{---C(=O)NH}_2$

which comprises reacting (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-formyl)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide of Formula IX



FORMULA IX


with Ag_2O to produce (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-carboxy)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide of Formula XIII followed by reacting (S)-N-[[3-Fluoro-4-[N-1[4-(2-furyl- (5-carboxy-ethyl)methyl)piperazinyl] phenyl]- 2-oxo-5-oxazolidinyl]methyl] acetamide of Formula XIII




FORMULA XIII

with aqueous ammonia to produce Formula XIV.


23. A process for the preparation of the compound of Formula XIV



FORMULA XIV




which comprises reacting (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-formyl)-methyl}] piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide of Formula IX



FORMULA IX


with Ag_2O to produce (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-carboxy)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide of Formula XIII followed by reacting (S)-N-[[3-Fluoro-4-[N-1[4-(2-furyl- (5-carboxyethyl)methyl)piperazinyl] phenyl]- 2-oxo-5-oxazolidinyl]methyl] acetamide of Formula XIII




FORMULA XIII

with thionyl chloride to produce Formula XIV.


24. A process for the preparation of the compound of Formula XIV



FORMULA XIV




which comprises reacting (S)-N-[[3-Fluoro-4-[N-1[4-{2-furyl(5-formyl)-methyl}] piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide of Formula IX



FORMULA IX

with Ag_2O to produce (S)-N-[[[3-Fluoro-4-[N-1[4-{2-furyl(5-carboxy)methyl}]piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] acetamide of Formula XIII followed by reacting (S)-N-[[[3-Fluoro-4-[N-1[4-(2-furyl- (5-carboxyethyl)methyl)piperazinyl] phenyl]- 2-oxo-5-oxazolidinyl]methyl] acetamide of Formula XIII



FORMULA XIII

with morpholine in the presence of oxalyl chloride to produce Formula XIV.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/IB 01/01262

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D413/14 C07D413/12 A61K31/42

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, WPI Data, EPO-Internal, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PAE, AE NIM ET AL: "Synthesis and in vitro activity of new oxazolidinone antibacterial agents having substituted isoxazoles" BIOORG. MED. CHEM. LETT. (1999), 9(18), 2679-2684, XP004179951 page 2681; table 1 page 2682; table 2	1-24
X	PAE, AE NIM ET AL: "3D QSAR studies on new oxazolidinone antibacterial agents by comparative molecular field analysis" BIOORG. MED. CHEM. LETT. (1999), 9(18), 2685-2690, XP004179952 page 2688; table 2 page 2689; table 3	1-24

-/--



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

28 November 2001

Date of mailing of the international search report

06/12/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Samsam Bakhtiary, M

INTERNATIONAL SEARCH REPORT

Int onal Application No

PCT/IB 01/01262

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 93 23384 A (UPJOHN CO., USA) 25 November 1993 (1993-11-25) page 36; example 20 claim 1 Y=i),j),k),m)	1-24
X	WO 95 25106 A (UPJOHN CO ;YAMADA HIROYOSHI (JP); MUNESADA KIYOTAKA (JP); TANIGUCH) 21 September 1995 (1995-09-21) page 39, line 1-10	1,4-24
Y	page 50, line 1-8 page 42, line 15-23 claim 1	2,3
X	US 5 547 950 A (HUTCHINSON DOUGLAS K ET AL) 20 August 1996 (1996-08-20)	1,4-24
Y	column 34; example 20 claim 1	2,3
X	WO 97 14690 A (ZENECA LTD ;GRAVESTOCK MICHAEL BARRY (GB)) 24 April 1997 (1997-04-24)	1,4-24
Y	claim 1 R5=benzyl	2,3
X	US 5 700 799 A (BARBACHYN MICHAEL R ET AL) 23 December 1997 (1997-12-23)	1,4-24
Y	column 34; example 20 claim 1	2,3
X	WO 00 32599 A (HESTER JACKSON B JR ;NIDY ELDON GEORGE (US); PERRICONE SALVATORE C) 8 June 2000 (2000-06-08)	1,4-24
Y	claim 1	2,3
Y	WO 98 01446 A (DARBYSHIRE CATHERINE JANE ;ZENECA LTD (GB); BETTS MICHAEL JOHN (GB) 15 January 1998 (1998-01-15) claim 1	1-24
Y	US 5 981 528 A (GRAVESTOCK MICHAEL BARRY) 9 November 1999 (1999-11-09) claim 1	1-24
Y	WO 95 14684 A (UPJOHN CO ;BRICKNER STEVEN J (US); BARBACHYN MICHEL R (US); HUTCHI) 1 June 1995 (1995-06-01) claim 1	1-24

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 01/01262

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9323384	A	25-11-1993	AU 668733 B2	16-05-1996
			AU 4287793 A	13-12-1993
			CA 2133079 A1	25-11-1993
			CN 1079964 A ,B	29-12-1993
			CZ 9402505 A3	16-08-1995
			EP 0640077 A1	01-03-1995
			FI 945246 A	08-11-1994
			HU 72296 A2	29-04-1996
			HU 9500659 A3	28-11-1995
			IL 105555 A	15-07-1998
			JP 7506829 T	27-07-1995
			MX 9302665 A1	01-11-1993
			NO 944237 A	04-01-1995
			PL 174909 B1	30-10-1998
			PL 174850 B1	30-09-1998
			RU 2105003 C1	20-02-1998
			SK 133794 A3	07-06-1995
			WO 9323384 A1	25-11-1993
			US 5547950 A	20-08-1996
			US 5700799 A	23-12-1997
			ZA 9302855 A	24-10-1994
WO 9525106	A	21-09-1995	JP 8073455 A	19-03-1996
			AU 681953 B2	11-09-1997
			AU 2099995 A	03-10-1995
			CA 2183972 A1	21-09-1995
			CN 1143961 A	26-02-1997
			EP 0750618 A1	02-01-1997
			JP 9512785 T	22-12-1997
			NZ 283011 A	22-09-1997
			WO 9525106 A1	21-09-1995
			US 5668286 A	16-09-1997
US 5547950	A	20-08-1996	US 5700799 A	23-12-1997
			AU 668733 B2	16-05-1996
			AU 4287793 A	13-12-1993
			CA 2133079 A1	25-11-1993
			CN 1079964 A ,B	29-12-1993
			CZ 9402505 A3	16-08-1995
			EP 0640077 A1	01-03-1995
			FI 945246 A	08-11-1994
			HU 72296 A2	29-04-1996
			HU 9500659 A3	28-11-1995
			IL 105555 A	15-07-1998
			JP 7506829 T	27-07-1995
			MX 9302665 A1	01-11-1993
			NO 944237 A	04-01-1995
			PL 174909 B1	30-10-1998
			PL 174850 B1	30-09-1998
			RU 2105003 C1	20-02-1998
			SK 133794 A3	07-06-1995
			WO 9323384 A1	25-11-1993
			ZA 9302855 A	24-10-1994
WO 9714690	A	24-04-1997	AU 7224896 A	07-05-1997
			EP 0858453 A1	19-08-1998
			WO 9714690 A1	24-04-1997
			JP 11513680 T	24-11-1999

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PC 1 / IB 01/01262

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5700799	A	23-12-1997	US 5547950 A	20-08-1996
			AU 668733 B2	16-05-1996
			AU 4287793 A	13-12-1993
			CA 2133079 A1	25-11-1993
			CN 1079964 A ,B	29-12-1993
			CZ 9402505 A3	16-08-1995
			EP 0640077 A1	01-03-1995
			FI 945246 A	08-11-1994
			HU 72296 A2	29-04-1996
			HU 9500659 A3	28-11-1995
			IL 105555 A	15-07-1998
			JP 7506829 T	27-07-1995
			MX 9302665 A1	01-11-1993
			NO 944237 A	04-01-1995
			PL 174909 B1	30-10-1998
			PL 174850 B1	30-09-1998
			RU 2105003 C1	20-02-1998
			SK 133794 A3	07-06-1995
			WO 9323384 A1	25-11-1993
			ZA 9302855 A	24-10-1994
WO 0032599	A	08-06-2000	WO 0032599 A1	08-06-2000
			AU 1705399 A	19-06-2000
			EP 1133493 A1	19-09-2001
WO 9801446	A	15-01-1998	AU 3352097 A	02-02-1998
			EP 0918769 A1	02-06-1999
			WO 9801446 A1	15-01-1998
			JP 2000514083 T	24-10-2000
US 5981528	A	09-11-1999	AU 1805397 A	10-09-1997
			EP 0882042 A1	09-12-1998
			WO 9730995 A1	28-08-1997
			JP 11514662 T	14-12-1999
			US 6271383 B1	07-08-2001
WO 9514684	A	01-06-1995	AT 182142 T	15-07-1999
			AU 698699 B2	05-11-1998
			AU 8010394 A	13-06-1995
			CA 2174107 A1	01-06-1995
			CN 1135752 A ,B	13-11-1996
			DE 69419523 D1	19-08-1999
			DE 69419523 T2	25-11-1999
			DK 730591 T3	31-01-2000
			EP 0730591 A1	11-09-1996
			ES 2133588 T3	16-09-1999
			GR 3031420 T3	31-01-2000
			JP 9505582 T	03-06-1997
			LV 12538 A	20-10-2000
			LV 12538 B	20-12-2000
			NZ 274966 A	26-01-1998
			SI 730591 T1	31-12-1999
			TW 427987 B	01-04-2001
			WO 9514684 A1	01-06-1995
			US 5652238 A	29-07-1997
			ZA 9407885 A	09-04-1996